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In the past decade, numerous groups have reported studies using genome-wide 
gene expression data generated from microarray. One of the blooming fields for 
microarray application is cancer research. Despite the promising nature of these 
initial microarray studies, such conventional approaches are associated with 
certain limitations. Because of these challenges, it is important to develop new 
methods to mine the inherent richness of information present in genome-wide 
expression data, in order to further identify novel, robust, and biologically-
relevant molecular signatures for the purposes of tumor classification and patient 
stratification.  
We applied the signature analysis (SA), which was designed to overcome 
the limitations of conventional clustering approaches, to a set of breast cancer 
expression profiles and successfully defined multiple ‘tumor modules’ (TuMs), 
each associated with a distinct biological function. Most significantly, the SA 
identified a previously-unreported module (TuM1) in a subset of Estrogen 
Receptor (ER+) tumors containing genes significantly enriched in cell death and 
apoptosis. The TuM1 module is not discernible by conventional clustering 
analysis; and proved to be a robust signature by repeated random sampling assays. 
We further show that tumors expressing the TuM1 module are associated with low 
histologic grade (P<0.001), and that this association is independent of a tumors’ 
inherent ER status and observed across multiple independent data sets 
representing distinct patient populations and array technologies. We also find that 
in vitro the TuM1 module is downregulated upon treatment with tamoxifen; and 
 VIII 
the knock down of TuM1 genes inhibit the tamoxifenf-induced apoptosis. 
Moreover, we showed that TuM1 expression in primary tumors may identify 
cancers more likely to respond to anti-hormonal therapy.  
Genetic components balancing pro and anti-oncogenic signaling pathways 
in cancers are likely to require precise regulation, as even subtle alterations in 
their expression may disrupt this balance with significant consequences on tumor 
growth and survival. Such precise regulation will be reflected by the tight range of 
expression variation. However, the conventional methods used in microarray 
studies focus on the expression level. Here, we identified a panel of 48 genes 
exhibiting highly restricted levels of gene expression variation in tumors 
compared to nonmalignant tissues. This tumor-specific “Poised Gene Cassette” 
(PGC) was robustly validated across ~1300 samples from multiple cancer types. 
This gene set is not readily detected by conventional methods (eg, t-test). In three 
separate experimental models, subtle alterations in PGC expression were 
consistently associated with significant differences in metastatic and invasive 
potential. This association was functionally confirmed in siRNA experiments, and 
in primary tumors similar subtle alterations in PGC expression were also 
associated with clinical outcome in multiple cohorts. These findings support the 
existence of a common set of precisely-controlled genes in solid tumors.  
By identifying novel clinically-relevant molecular signatures in cancer, our 
results thus demonstrate that novel approaches to gene expression data can 
successfully reveal novel biological information even from data sets that have 
received substantial prior analysis. 
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Chapter 1. Introduction – Gene Expression and 
microarray 
In this chapter I will introduce the concept of gene expression, an essential 
phenomenon of biological system; and the technology, namely microarray, to 
measure the gene expression in a high-throughput manner. A brief description of 
methods for microarray data analysis will be given in this chapter. This chapter 
will end in discussing the rationales and limitations of analytical methods which 
have been widely used in analyzing gene expression data generated by microarray.    
 
1.1 Gene Expression  
Gene is the fundamental physical unit of heredity that transmits information from 
one cell to another and hence one generation to another. Genes consist of 
deoxyribonucleic acid (DNA) sequences. Gene expression is the process by which 
the inheritable information embedded in a gene is manifested as a physical and 
biologically functional gene product, such as protein or RNA. The central dogma 
of molecular biology (Figure 1.1), first put forward by Francis Crick in 1958 (1), 
describes the flow of genetic information from gene to protein: the messenger 
ribonucleic acid (mRNA) is made from the gene through a process called 
transcription; the protein is then made from the mRNA through a process called 
translation. There is an intermediate step called ‘splicing’, which is a modification 
of RNA after transcription and before translation. The physical development and 
phenotype of organisms can be thought of as a product of genes (eg, protein) 
interacting with each other and with the environment. The proper expression of a 
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large number of genes is critical for the normal growth development and 
maintenance of the proper health. Disruptions or changes in gene expression are 
responsible for many diseases such as cancer.  
 
 
Figure 1.1  The central dogma of molecular biology.   
Source: http://users.ugent.be/~avierstr/principles/centraldogma.html. 
 
Gene regulation, via gene expression, gives the cell control over structure 
and function. The expression of many genes is regulated by transcription. Hence 
the amount of a specific mRNA transcribed from a specific gene is proportional to 
the amount of the specific protein to be translated from that mRNA. Therefore, the 
amount of a specific mRNA can be used as a measurement of the expression level 
of the gene from which that mRNA is transcribed.  The measurement of the 
 3 
amount of the mRNA is called as gene expression data. mRNA levels can be 
measured in the low-throughput approaches, such as real-time polymerase chain 
reaction (RT-PCR) or Northern blotting. In addition to low-throughput methods, 
transcript levels for many genes can be simultaneously measured with DNA 
microarray technology or "tag based" technologies like Serial analysis of gene 
expression (SAGE). In this thesis, we will focus on the gene expression data 
generated by microarray technology; though the methods and concepts are 
generally applicable to other types of gene expression data.  
  
1.2 microarray 
Recent advances in microarray technology allow for the quantification, on a single 
array, of the transcript levels for every known gene in the human genome. The 
type of microarray used in the measurement of gene expression is called DNA 
microarray (also commonly known as DNA Chip or Gene Chip). There are other 
types of microarrays such as protein microarray and tissue micorarray, which are 
named base on the biological materials deposited on the surface of the array. DNA 
microarray is a chip that has a array of DNA fragments or oligonucleotides 
(probes) immobilized on a solid surface (2). These DNA fragments or 
oligonucleotides are located at discrete addresses where the fragments are 
available for hybridization with mRNA from a sample (target). The brief of 
principle of hybridization is that two perfectly complementary strands of 
nucleotides (ie, probes and target) will readily bind to each other. A nucleotide is a 
chemical compound that consists of a heterocyclic base, a sugar, and one or more 
phosphate groups. DNA and mRNA are each made of a chain of nucleotides. 
Thus, if we attach the complementary strands of the mRNA we want to measure 
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on a given spot on the chip, the level of hybridization (i.e., the amount of mRNA 
which binds to the spot) indicates the amount of the mRNA present in the sample 
that is being measured. To enable the measurement of the amount of 
hybridization, fluorescent or radioactive dye is used to label the mRNA from 
samples (target). An example of microarray experiment has been given in Figure 
1.2. 
 
Figure 1.2  A Workflow of microarray Experiment 
This figure is adopted from wikipedia: 
http://en.wikipedia.org/wiki/DNA_microarray). The mRNA is derived from 
cancer cells and normal cells, respectively. After the reverse transcription, cDNA 
is labeled with different fluorescent and hybridized to the microarray, The 
intensity signal is measured by reading the fluorescent on the spot. 
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There are two-types of DNA microarray: cDNA (complementary DNA) 
arrays (3) and high-density oligonucleotide chips (4). They differ from each other 
in the two aspects: 1) the type of complementary strand of the mRNA attached to 
the spot on the chips: cDNA in cDNA arrays and oligonucleotides in high-density 
oligonucleotide chips; and 2) whether a control sample is needed (in addition to 
the sample of interest) in order to quantify the amount of hybridization: a control 
sample is necessary for cDNA arrays but not for high-density oligonucleotides 
chips. Figure 1.2 illustrates an example of cDNA arrays. With the implementation 
of the appropriate data preprocessing and normalization procedures, the 
microarray data can be analyzed in a similar way regardless of the technology 
used for the microarray chips. 
Microarray is designed to measure the gene expression in a sample. A 
sample of interest, or sample for short, consists of a cell line or tissue of interest.  
A typical microarray dataset consists of gene expression data from a collection of 
M samples.  M is variable, depends on the purpose of the project. The dataset can 
be defined using a MN × matrix where N denotes the number of genes in the 
dataset, and M denotes the number of samples in the dataset. A value in the matrix 
can be represented as X = (xi,j)N×M where xi,j represents the expression of gene i in 
sample j.  Since a typical microarray dataset is high-dimensional with a relatively 
small number of samples, we have MN >> . 
Microarray has recently commonly used in biological research. A few 
typical examples of microarray application would include comparing healthy and 
malignant tissue, studying cell phenomena over time, as well as studying the 
effect of various factors such as oncogene transfection on the overall pattern of 
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expression. Perhaps more importantly, it has been shown that microarrays can be 
used to generate accurate, precise and reliable gene expression data (5, 6).  
 
1.3 Methods for microarray Data Analysis 
With the rapid application of microarray technology and the growth of microarray 
data in an exponential order, numerous methods for microarray analysis have been 
reported. Generally speaking, there are several key components of microarray data 
analysis : 1) experimental design; 2) preprocessing includes image analysis and 
normalization; 3) inference and classification; and 4) validation. Though the first 
two components are very important, in this thesis we will focus on 3) and 4) – 
classification and validation. 
There are two broad categories of methods used for microarray data 
analysis, after the proper data preprocess. Many developed methods are special 
cases of these two categories. One category is unsupervised learning methods that 
are represented by clustering methods. The other is supervised learning methods 
such as t-test and other sophisticated methods like support vector machine (SVM). 
The obvious difference between unsupervised and supervised methods is that 
unsupervised methods do not require prior knowledge; while supervised learning 




Class A Class B
Known Samples
Gene Signature and 
Predictive Model





Figure 1.3 The scheme of unsupervised learning and supervised learning. 
The left panel is the unsupervised learning and the right panel is the supervised 
learning. 
 
Unsupervised analysis is ideal for situations where we have little a priori 
knowledge of the complete repertoire of expected gene expression patterns for any 
condition (7).  The most popular unsupervised analysis method is probably 
clustering. Clustering may be done gene-wise or sample-wise, or both. In the 
gene-wise clustering, groups of genes with similar expression patterns are formed. 
In the sample-wise clustering, groups of samples with similar gene expression 
patterns are formed. The objects (genes or samples) in a group are more alike than 
the objects across different groups in terms of gene expression pattern. The aim of 
clustering is to group similar objects and then to visualize the relationship and 
distance between objects.   
Many of the probes on microarray chips represent genes whose functions 
are still unknown. In gene-wise clustering, the functions of these genes may be 
inferred by looking at genes with known functions which belong to the same 
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group. This type of inference is based on the guilt-by-association principle. For 
example, if Gene X, a gene with unknown function, belongs to the same group as 
a gene known to be involved in promoting cell growth, we may infer that Gene X 
is also involved in promoting cell growth or related functions such as cell division. 
Sample-wise clustering allows the discovery of hitherto unknown groups of 
biological phenotypes among tissues or cell lines, leading to post-analysis 
labeling. Chapter 2 will discuss a few successful applications of clustering 
methods in microarray studies. Several clustering techniques have been applied on 
microarray datasets: hierarchical clustering (7, 8), k-means clustering (9), and 
self-organizing maps (10). Briefly, these clustering methods calculated the 
correlation coefficient between expression data of genes or samples to quantify 
the similarity among genes or samples.  
Supervised analysis relies on existing a priori knowledge of distinct groups 
among the samples in the dataset. Examples of supervised analysis are 
classification. The molecular classification involves the classification of samples 
into groups of biological phenotypes. With the advent of the microarray 
technology, data regarding the gene expression levels now prove to be a useful 
tool in molecular classification (discussed in Chapter 2). Classification methods 
which are based on datasets have long existed in the field of supervised machine 
learning and statistical test. To implement these classification methods on 
microarray datasets, the following steps are conducted: 
(a) microarray experiments are first conducted in order to produce gene 
expression data for the samples of interest (e.g., each sample may 
represent tumor tissue from a patient).   
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(b) Samples are then labeled and grouped into the appropriate class, based 
on the grouping of interest.  For example, we may have a group where 
each class represents a disease or non-disease.   
(c) Next, using a statistical student t-test to find genes significantly 
differentially expressed between classes of samples (11, 12). 
Alternatively, a supervised machine learning method such as support 
vector machine (SVM, (13)) can be used to build a classifier from the 
dataset containing the labeled samples.   
(d) The gene expression data of a new sample is first obtained using 
microarray chip.  
(e) The classifier is used to predict the class (or the ‘label’) of the new 
sample (e.g., the tumor type or subtype, or resistance to a particular 
anticancer drug).      
 
Supervised learning methods haven been used to identify ‘gene signatures’ 
of a particular disease that provides a diagnostic power; to predict survival of 
patients (prognostic); or to justify the patient’s response to the drugs. The 
applications of supervised methods in microarray studies will also be discussed in 
Chapter 2.  
 
1.4 Limitations of Conventional microarray data analysis 
Despite the promising nature of the initial applications of data analysis methods in 
microarray studies, such standard approaches of microrarray data analysis are 
associated with certain limitations. For example, unsupervised algorithms such as 
hierarchical clustering (HC) typically cluster genes based on their global behavior 
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across all samples or experimental conditions in the data set, when in reality 
certain genes may only show strong regulation in a certain subset of tumors, and 
weak to minimal regulation in others (14, 15).  
The expression variation has also been largely ignored in these convention 
studies. Most of microarray studies focus on genes that either overexpressed or 
underexpressed. Such measurements reflect the change at the absolute expression 
level. However, some important biological phenomenon may be reflected at 
expression variation level. For instance, precise regulation of signal flow is a 
common feature of many biological networks. The genes under precise regulation 
may exhibit a narrow range of expression variation as its expression is tightly 
regulated. Biology network usually shows inherent robustness against various 
perturbations (16). However, some gene show hypersensitivity to the perturbation, 
where very small changes in stimuli can suffice to elicit qualitative changes in 
output (17, 18). We may hypothesize that such hypersensitivity components may 
exhibit a restricted level of express variation, reflecting the tight transcription 
regulation. This suggests the analysis on the expression variation, rather than the 
change at the absolute expression level, may lead us to unravel the potential 
precise regulation and hypersensitivity components. Unfortunately, to our 
knowledge, the expression variation in microarray studies have been only used to 
identify ‘housekeeping’ genes that are stably and ubiquitously expressed in 
multiple tissues and conditions. Interest in these ‘control’ genes has been 
primarily driven by the fact that on a practical level, such genes are often used as 
internal controls and normalization standards for a variety of biological 
experiments. 
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Because of these challenges, it is important to develop new methods to 
mine the inherent richness of information present in genome-wide expression 
data, in order to further identify novel, robust, and biologically-relevant molecular 
signatures for the purposes of better understanding of diseases studied by 
microarray gene expression technologies. 
 
1.5 Thesis Organization 
This thesis begins with background on microarray and gene expression, followed 
by the introduction of analytical methods used in microarray studies.  
We briefly describe the basic concept of cancer in Chapter 2, followed by 
the examples and literature reviews of the microarray applications in cancer 
research. 
We introduce the tumor module – a conditional gene cluster in Chapter 3. 
This method overcomes the limitation of conventional unsupervised methods (ie, 
hierarchical clustering). We show the identification of novel tumor module in 
breast cancer. The biological significance and clinical implication of the tumor 
module is also addressed in the Chapter 3. The main body of this work has been 
published in the Clinical Cancer Research (19). A paper that is in press reported a 
prospective clinical validation of the tumor module signature (20).  
Chapter 4 provides another novel angle to explore the microarray data.  By 
analyzing the expression variation in cancers, rather than the absolute expression 
level, we found cancer-specific ‘poised gene cassette’, which showed a tight range 
of expression variation. These genes cannot be detected by conventional methods 
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like t-test. We further explored the functional role of ‘poised gene cassette’ in 
cancer. This work has been accepted by PLOS Genetics. 
Chapter 5 includes the conclusion of the thesis. We end our thesis with a 










Chapter 2. microarray Studies of Cancer Genomics 
2.1 Cancer 
Cancer is the most deadly disease worldwide. Cancer cause about 13% of all the 
death worldwide (21). Cancer is a disease characterized by abnormal cell growth 
and proliferation (cell dividing) that is beyond normal limits (Figure 2.1). Hence 
cancer is due to the failure in the mechanisms that control the growth and 
proliferation of cells. These altered cells eventually grow into a tumor. Cancer 
cells may invade and destroy adjacent tissues, and may spread to distant anatomic 
sites through a process called metastasis. In this thesis, the term cancer and tumor 
are used interchangeable.  
The losses of normal cellular regulation mechanisms that give rise to 
cancers are generally due to genetic change. The genetic changes usually are 
referred to mutations, changes to the base pair sequence of gene. The disruption of 
gene expression (both mRNA and protein level) are also common in cancer 
development. New aspects of the genetics (or epigenetic) of cancer pathogenesis, 
such as DNA methylation, and microRNAs are increasingly being recognized as 
important.  
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Figure 2.1  The hall markers of cancer  
This figure is adopted from Hanahan, D and Weinberg, RA (22). Six fundamental 
cellular properties can be altered during carcinogenesis, to give rise to the caner 
phenotype. Apoptosis is cell death. Angiogenesis is a process involving the 
growth of new blood vessels, in this case to provide supply for cancer cells.   
 
Traditional approaches to study tumor and normal samples are based on 
staining and microscopy, which is used to tell the difference in cell morphology. 
However, the appearance of cells alone provides very limited information. Better 
methods are desirable both to understand tumorigenesis and to arrive at 
meaningful and accurate decisions about prognosis and therapy. Genetic studies 
showed that at the cellular level only single mutation or a series of mutations can 
transform normal cells to tumor cells. However, the tumor cells undergo a cascade 
of changes reflecting the interplay with the environment. As a result, tumor cells 
can become quite different, even they arises from the same initial event (eg, 
mutation). These differences may not be visible from the appearances of cells, but 
can be detected by the gene expression patterns of the cells. DNA microarray 
technology can detect the expression of thousands of genes simultaneously, 
permitting complex phenotype of cancer cells to be defined at molecular genetic 
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level. DNA microarray has been widely used in cancer research. In the section 2.2 
we will discuss the applications of DNA microarray in cancer research.  
  
2.2 microarray Application in Cancer Research 
microarray technology greatly propelled the gene expression study. In the past 
decade or so, microarray has been widely used in cancer research. Till December 
31st 2007, there are 22,382 articles with keyword ‘microarray’ found in 
PUBMED (http://www.ncbi.nlm.nih.gov/sites/entrez). Among these microarray-
related studies, 7,036 (31%) were conduced in cancer research (ie, concurred with 
keyword ‘cancer’). microarray-based gene expression data have been used to 
identify previously unknown molecular subtypes of cancer; prognostic markers to 
predict patients’ survival outcome; gene signatures to predict the drug responses; 
or decode gene expression changes upon oncogene activation. Here we highlight a 
few examples in each category:  
I) Molecular subtypes of cancer: Unsupervised clustering methods can 
measure the similarity of gene expression patterns between genes or samples. 
Based on the similarity measurement, the clustering algorithms can group 
genes/samples into subgroups distinguished by pervasive differences in their gene 
expression patterns. For example, in 1999, a research team led by TR Golub and 
ES Lander used microarray-based gene expression data and unsupervised 
clustering method to discover two distinct molecular subtypes of human acute 
leukemia cancer (10). This is the one of the first reports about the approach to 
cancer classification based on gene expression measured by DNA microarray. In 
2000, a research group from Stanford University reported a molecular portrait of 
breast cancer (8). In this report, the authors revealed a striking heterogeneous gene 
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expression pattern among breast tumor samples. The authors identified a number 
of co-expressed gene groups, in which genes exhibited similar expression patterns. 
The authors suggested that for the co-expressed genes the variation in the mRNA 
levels could be related to the physiological variation among tumors; hence the 
tumors could be divided into subgroups with distinct difference in their expression 
patterns. In this and a subsequent study (23), with a larger collection of breast 
tumor samples, the authors reported at least three subtypes of breast cancer: 1) 
Luminal epithelial/estrogen receptor positive tumor subtype, which was further 
divided into two subgroups; 2) an ERBB2 overexpression tumor subtype; and 3) 
Basal epithelial/estrogen receptor negative tumor subtype (Figure 2.2).  Moreover, 
this report showed that the patients belonging to the various groups have 
significantly different outcomes (23). These results suggest gene expression data 
from DNA microarray can reveal subtypes of cancer with not only heterogeneous 
molecular patterns, but also distinct characteristics to clinical outcome. The 
subtypes have been repeatedly observed in an independent data sets (24). Our 
group has also reported the conservation of breast cancer subtypes in an Asian-
Chinese patient population (25). The subtypes have also been demonstrated to be 
presented in pre-invasive stage of carcinogenesis (25) and metastasis tumors (26). 
These results strongly support the idea that these breast tumor subtypes represent 









Figure 2.2  The molecular subtypes of breast cancer   
(adopted from Sorliet et al., 2001 (23)). The hierarchical clustering divided breast 
tumor samples into five (or six) subtypes based on differences in gene expression 
(A). The full cluster diagram (B) scaled down to five co-expressed gene cluster 
exhibiting distinct expression patterns among subtypes. The full figure legend can 
be found in reference (23).  
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II) Prognostic markers: Patients have different survival outcomes, even with 
the similar clinical behavior. Chemotherapy or hormonal therapy reduces the risk 
of distant metastases by approximately one-third; however, 70–80% of breast 
cancer patients receiving this treatment would have survived without it (12). If we 
are able to predict the patient survival outcome (prognostication), we can tell 
which patient should receive adjuvant treatment. Hence a more accurate means of 
prognostication in cancer will improve the selection of patients for adjuvant 
systemic therapy. A group of patients with known survival outcome (ie, a good 
follow-up record) and their expression profiling of tumor cells may allow us to 
build a predictive model based on gene expression patterns. Once a new patient 
comes in, we can predict his or her survival outcome based on the expression 
pattern of his or her tumor cells. One of the best studies in identification of 
prognostic markers is a Nature paper published in 2002. As shown in Figure 2.3, 
Van’t veer and his colleagues established a 70-gene expression signature, whose 
expression level were associated with either good prognosis or poor prognosis, 
from 79 lymph-node-negative, early stage young breast cancer patients (12). Later 
in 2002, the same research group validated the 70-gene signature in a larger 
patient cohort (295 consecutive patients) (27). In this study, the authors also 
showed that the 70-gene signature was a strong independent factor, among various 
clinical parameters, in predicting disease outcome. The authors hence suggested 
that the gene-expression profile study is a more powerful predictor of the outcome 
than standard systems based on clinical and histological criteria. The 70-gene 
signature was subsequently validated in independent patient population (28), or 
gene expression data measured by different technologies. Recently, the 70-gene 
signature has been developed into the diagnostic test (MammaPrint®), which was 
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cleared by Unite Stated Food and Drug Administration (FDA) in February 2007. 
These results showed very encouraging prospect of prognostic markers derived 
from gene expression data. 
 
 
Figure 2.3  The prognostic signature for breast cancer   
(adopted from Van’t veer et al., 2002 (23)). A) The patients were defined into two 
groups based on whether they developed metastases within five years. A simple 
voting stratergy was used to find gene signatures that are upregulate or 
downregulated in one of the class, relative to the other one. B) The expression 
patterns of the gene signatures among the tumor samples.  
 
III) Drug response prediction: One challenging problem in cancer therapy is 
that cancer patients show heterogeneous responses to the same drug, even with 
similar clinical and histological behaviors. For instance, tamoxifen, an orally 
active selective estrogen receptor modulator (SERM), is used in the treatment of 
estrogen receptor-positive breast cancer patients. Tamoxifen is thought to act 
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primarily as a competitive inhibitor of estrogen binding to estrogen receptor (ER). 
In clinical practice, most patients with ER-positive tumors are treated with 
adjuvant tamoxifen therapy. However, ~40% of ER+ breast cancers fail to 
respond or eventually develop resistance to tamoxifen (29, 30), leading to disease 
progression. Current clinicopathological features including tumor stage, grade, 
ERBB2 and EGFR expression fail to accurately identify individuals who are at 
risk for tumor recurrence. Dennis C. Sogri and his colleagues used microarray to 
generate gene expression profiles of ER+ primary breast cancers in a set of 60 
patients treated with adjuvant tamoxifen monotherapy (ie, treated with tamoxifen 
only). They reported a two-gene expression ratio (HOXB13 and IL17BR) that can 
predict disease-free survival and outperformed existing biomarkers (31). The 
prognostic capability of this HOXB13-to-IL17BR expression ratio was further 
validated in a larger patient cohort by quantitative reverse transcription-PCR 
profiles (32). A recent study screened more than 1,250 patients and further 
confirmed that the HOXB13-to-IL17BR expression ratio expression levels 
associate with both tumor aggressiveness and tamoxifen therapy response (33). 
These results suggest the different response to the drug is likely arisen from the 
heterogeneity in the molecular character of tumor cells. 
IV) Oncogenic pathway – understanding cancer better: The development of a 
cancer is a complex process involving the accumulation of multiple independent 
mutations that lead to deregulation of cell signaling pathways central to the 
control of cell growth and cell fate. The activation status of these oncogenetic 
pathways may reflect the biological and outcome of specific cancer; and shed the 
light on the targeted therapeutics. Gene expression profiling has been used to 
analyze the oncogenic pathways regulated by RAS, E2F1, MYC, and other 
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oncogenes (34, 35). The model of gene expression patterns generated by 
dysfunctional MYC or RAS proteins in in vitro tissue culture cells successfully 
predict the in vivo tumor models in which the MYC or RAS pathways were 
deregulated. The author concluded that “these gene expression phenotypes have 
the potential to characterize the complex genetic alterations that typify the 
neoplastic state, whether in vitro or in vivo, in a way that truly reflects the 
complexity of the regulatory pathways that are affected” (35). Furthermore, these 
oncogenic pathway signatures have later been shown to predict the response to 
therapeutic agents that target components of the pathway (36). These data provide 
an exciting opportunity to apply the oncogenic pathway signatures to guide the 
use of targeted therapeutics. 
In a summary, microarray studies in cancer enhance our understanding of 




2.3 Novel data analysis methods to refine the molecular 
profiling of cancer 
microarray data of cancer cells have been extensively analyzed and led to 
numerous breakthrough findings. However, as we discussed in the section 1.4, 
there are certain limitations of the conventional microarray data analysis methods. 
To further extract the novel knowledge embedded deeply in the richness of 
microarray gene expression data, we developed and applied two novel data 
analysis approaches on the microarray data in the context of cancer study. We will 
demonstrate, in the next two chapters, that the novel methods successfully 
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revealed novel biological and clinical –relevant information in cancers, even from 
data sets that have received substantial prior analysis. Moreover, the novel 
methods and the expression patterns identified by these methods are generally 




Chapter 3. Tumor Modules in Breast Cancer 
 
3.1 Breast Cancer 
Breast cancer is a significant cause of worldwide morbidity and mortality in 
females (37). A major challenge in the diagnosis and treatment of breast cancer is 
its heterogeneity, as individual breast tumors can exhibit tremendous variations in 
clinical presentation, disease aggressiveness, and treatment response (38). For 
example, one important factor in clinical breast cancer classification include 
determining the estrogen receptor (ER), as ER is a prognostic biomarker (39) and 
important predictive markers of treatment response to anti-hormonal therapy (40). 
In the clinical practice, the absolute levels of ER expression, as well as the 
progesterone receptor (PR, an indicator of a functional ER pathway), are currently 
the best predictors of tamoxifen response. However, 25% of ER+/PR+ tumors, 
66% of ER+/PR− cases, and 55% of ER−/PR+ cases fail to respond, or develop 
early resistance to tamoxifen (29, 30). 
In recent years, several groups have reported studies using genome-wide 
gene expression data to classify breast cancers for the purposes of molecular 
taxonomy (8, 23, 25), disease prognosis (12, 27), and treatment response 
prediction (31, 32).  These studies have applied standard unsupervised learning 
methods (eg, hierarchical clustering) or supervised learning methods (eg, t-test) in 
their microarray data analysis. As we discussed in Chapter 1.4, there are certain 
limitations associated with these conventional analysis methods. Unsupervised 
learning algorithms, such as Hierarchical clustering, typically cluster genes based 
on their global expression patterns across all samples (eg, tumors); while in reality 
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certain genes may only show strong regulation in a certain set of tumors, and 
weak to minimal regulation in others (14, 15). Standard clustering methods have 
also limited the assignment of a gene to a single cluster; while in a complex 
biological system a gene can have multiple functions and be involved in multiple 
pathways. These limitations are prominent in the analysis of large-scale 
microarray gene expression data; in which tens of thousands genes and hundreds 
samples are profiled.  
 
3.2 Signature Algorithm (SA) 
To overcome the limitations of conventional clustering methods, the alternative 
methods have been proposed to assign genes to context-dependent and potentially 
overlapping gene clusters – so-called ‘transcriptional modules’ (15). For example, 
Naama Barkai and colleagues have described a novel analytical approach, 
Signature Algorithm (SA), which was specifically designed to overcome the main 
limitations of conventional clustering methods. They applied SA to the sets of 
expression data on yeast Saccharomyces cerevisiae and identified a 
comprehensive set of transcriptional modules. Based on these modules, Barkai 
and his team provided functional predictions for many genes and presented a 
global view on the transcriptional network in the yeast (14, 15).  
Here we give out a brief description of Signature Algorithm (SA; Figure 
3.1): 1) SA starts with a selected set of ‘input genes’, which is used to query the 
gene expression data; 2) The SA selects those experiments (eg, tumors) where the 
average expression of the input genes is above a pre-defined threshold 
(experiment threshold), that is, tumors where the ‘input genes’ are overexpressed; 
3) The global profiles of these selected experiments are then examined to select 
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other genes whose average expression is above the gene threshold. The output of 
SA is a ‘transcriptional module’, comprising a set of genes that display expression 
levels above a particular threshold within a specific group of experiments. The 
‘transcriptional module’ reflects a condition-specific co-regulation expression 
pattern. 
 
Figure 3.1  The scheme of signature algorithm  
This figure is adopted from (15). The heatmap represents the matrix of gene 
expression data. Each row is a gene and each column is a sample. 
 
To evaluate the performance of the signature algorithm, a recurrence 
analysis was used to assess the robustness of a transcriptional module. If the genes 
in the input set were known to be co-regulated, the addition of many random 
genes leaves the output of the signature algorithm essentially unchanged (15). 
Based on this character of the module, we can assess whether there is a co-
regulated pattern embedded in the input set. As illustrated in Figure 3.2, a 
collection of new derived sets are created containing both the input genes and 
genes randomly selected from the entire data set. SA is then performed on both 
the input set and the derivation sets. If the input set has a meaningful co-regulated 
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pattern, then this pattern should be strongly preserved in the derivation sets, and 
consequently the various output modules will have a large overlap. On the other 
hand, if there is no co-regulated pattern embedded in the input set, the output 
modules will be quite different and little overlap will be observed. The details of 
recurrence analysis are further described in (15), which also provides a 
mathematical definition of the recurrence metric. 
Input set
Input set + 
random genes set I
Input set + 








Figure 3.2  The recurrence analysis to measure module robustness  
The output modules of the derived input sets are compared to assess their overall 
overlap. A detailed explanation can be found in (15).  
 
An extension of SA, the iterative signature algorithm (ISA), which utilizes 
a large number of random gene sets as the initial input and subsequently refines 
the transcriptional through multiple iterative rounds of recurrence analysis (15). 
The details of ISA regarding random gene sets generation and the mathematical 
definition of ISA are provided in (41). As the inputted gene sets are random, ISA 
does not require prior knowledge and hence constitutes an entirely unsupervised 
analytical approach.  
 
3.3 Tumor Module (TuM) 
The signature algorithm has been shown to be superior to conventional clustering 
methods (14). The previous application of signature algorithm is mainly focused 
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on yeast gene expression data. The concept of transcriptional module can be 
naturally extended to higher organisms like human. To our surprise, there is no 
study to apply the signature algorithm into human cancer, where there is one of 
richest resource of gene expression data (see chapter 2). In this study, we tested 
the hypothesis that novel biological information could be uncovered in these 
cancer data sets using this modular technique. In the context of cancer, we defined 
the term ‘Tumor Module’ (TuM): a group of co-regulated genes in a set of tumors 
in which the co-regulated genes are overexpressed. We then search for tumor 
modules in our collection of breast cancer tissue samples.  
 
3.4 Breast Tissues and microarray Profiling 
Primary human breast tumors were obtained from the National Cancer Centre of 
Singapore (NCC) Tissue Repository, after appropriate approvals from the NCC 
Repository and Ethics Committees. Samples were grossly dissected in the 
operating theater immediately after surgical excision, and flash-frozen in 
liquid N2. Samples had not been treated with pre-operative chemotherapy. For 
histological assessment of tumors and axillary lymph nodes, formalin-fixed, 
paraffin-embedded tumor tissue was used to determine tumor subtype (WHO 
classification), histologic grade, and lymphovascular invasion. Tumor size, based 
only on the invasive component, was assessed macroscopically and confirmed 
microscopically. For small tumors, the size was measured on this histologic 
section. ER status was determined by immnohistochemistry, with a positive result 
being >10% of carcinoma cells showing nuclear reactivity of at least +2 intensity. 
For ERBB2 immunohistochemistry, the Dako classification system was used with 
scores of 0 and 1+ considered negative while 2+ and 3+ were positive. An 
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indeterminate conclusion was made when benign breast epithelium was 
immunoreactive. A collection of 96 profiled samples containing at least 50% 
tumor content was used as the training set.  The clinical data is listed in Appendix 
Table 3.7. The independent collection of second data set which includes 86 breast 
tumors are short of clinical data. Profiled samples contained at least 50% tumor 
content.  
RNA was extracted from tissues and cell lines using Trizol (Invitrogen, 
Carlsbad, CA) reagent and processed for Affymetrix Genechip (Affymetrix Inc., 
Santa Clara, CA) hybridizations using U133A Genechips according to the 
manufacturer's instructions. The manufacturer’s instructions were followed for 
RNA labeling and hybridizations. The hybridization signal on the chip was 
scanned and processed by GeneSuite software (Affymetrix Inc., Santa Clara, CA). 
Raw Genechip scans were quality controlled using GeneDataTM Refiner 
(Genedata, Basel, Switzerland). MAS5 Statistical algorithm (Affymetrix Inc., 
Santa Clara, CA) was used to calculate the signal using the probe array’s 
hybridization intensities measured by the scanner. One-Step Tukey’s Biweight 
Estimate is used in MAS5 algorithm. The expression data was pre-processed by 
removing genes whose expression was absent in more than 40% samples (ie 'A' 
calls), subjecting the remaining genes (9116 probes) to a log2 transformation, and 
normalization by median-centering of samples. The expression data has been 
deposited into the Gene Expression Omnibus (GEO) database (GSE2294). 
 
3.5 Identification of Tumor Modules in Breast Cancer 
We applied iterated signature algorithm (ISA) to the gene expression profiles of a 
set of 96 breast cancer primary tumors. A series of tumor modules were generated 
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by a range of gene thresholds, which reflects how tightly the genes in a module 
are co-regulated (Figure 3.3). At low gene thresholds (left columns of Figure 3.3 
A), only a few TuMs are initially identified. The genes in these modules are 
loosely correlated. With the increase of gene threshold, the relaxed correlation 
patterns can be decomposed into several modules; each has a more tightly co-
regulated gene sets. Hence, a tree-like structure was formed along the increase of 
gene threshold (Figure 3.3A).  
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Figure 3.3  Tumor Modules of Breast Cancer 
A) A module tree of the tumor modules (TuMs) in the breast oncotranscriptome at 
different levels of resolution. Each node (solid blue rectangle) represents a tumor 
module. Branches represent TuMs that originate from the same roots over a range 
of thresholds. B) Global gene expression patterns within Tumor Modules. Each 
row represents one gene and each column represents one tumor. Eight diagonal 
blocks (separated by yellow grid) represent eight modules (under gene threshold 
3.0) from A). The legend of the eight modules is listed. The off-diagonal blocks 
reveal how genes in one module function in other modules. The red arrows show 
examples of genes and tumors that are shared between different modules. The 
heat-map bar shows the scale of gene expression value, with red indicating high 
expression and green indicating low expression. 
 
Base on the previous report (15) and the structure of our tumor module 
tree, we selected a gene threshold of 3.0 (second right column in Figure 3.3 A) as 
an optimal threshold for further analysis. At this threshold, we identified eight 
Tumor Modules (TuMs) in the expression data of 96 breast cancer primary 
tumors. First, we assess whether our TuMs can re-capture the previous reported 
‘molecular portrait’ of breast cancer (8), which was introduced in Chapter 2.2 and 
Figure 2.2. There are several important gene clusters been identified: 1) Immune 
response genes including immunoglobulin genes, T cell receptor subunits, and 
TNF family members; 2) Stromal cell – connective tissue cells which make up the 
support structure of biological tissues :  a cluster of genes involved in collagen 
binding, including several isoforms of collagen; 3) Basal epithelial cell type/ER- 
breast cancer: Keratin 5, Keratin 17, and SFRP1. Keratin 5 has been used a 
marker to stain the basal epithelial cells; 4) cell proliferation genes:  genes 
involved in cellular proliferation such as MAD2L1 and CDC2; and 5) ERBB2: 
genes physically linked to the ERBB2 amplicon at 17q21 locus including v-erb-b2 
(ERBB2), GRB7, and PNMT. These gene clusters have been successfully re-
identified in the tumor modules (TuM4 – TuM8, Figure 3.3). To further fit these 
modules into the biological context, we performed Gene Ontology analysis using 
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GoStat tool (42), a web application to identify terms of Gene Ontology (represent 
a group of genes with similar functional annotations) that are significantly 
enriched in the genes from a tumor module. Fisher's Exact Test was performed to 
calculate the significance of the observed enrichment, combined with a Benjamini 
and Hochberg correction to control the false discovery rate. GoStat is available at 
http://gostat.wehi.edu.au/cgi-bin/goStat.pl. As expected, the results showed a good 
agreement with ‘known functions’ of gene clusters. For example, we found out 
that cell cycle genes is significantly overexpressed (p=4.08*10-16) in TuM7 (cell 
proliferation); meanwhile extracellular matrix (ECM) (p=2.85*10-6) and collagen 
binding (p=8.72*10-6) are enriched in TuM5 (stromal). 
Taken collectively, these results validate the biological consistency of the 
TuMs. More generally, they demonstrate that despite being an entirely 
unsupervised analytical approach, the ISA appears to be remarkably efficient at 
re-discovering many, if not all, of the major gene expression signatures previously 
reported for breast cancer identified by conventional analysis.  
 
3.6 A Novel Module – TuM1 
TuM1, TuM2 and TuM3 were derived from a single larger module (Figure 3.3A). 
The larger module contained genes previously characterized as highly expressed 
in estrogen receptor-positive (ER+) tumors, such as ESR1, STC2, and BCL2 (8). 
In the previous reports, these ER-related genes forms one homogeneous cluster (8, 
23, 25). Interestingly, we noted that this cluster was decomposed into distinct 
smaller modules at the more stringent threshold. This result demonstrated the 
power of SA to identify distinct yet overlap tumor modules. Certain genes and 
tumors can be shared among tumor modules representing different entities. A 
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close look at gene content revealed that >80% of the genes in TuM1 (33 genes in 
total) are not found in either TuM2 (38 genes) or TuM3 (30 genes). To confirm 
the novelty of TuM1, we did a survey of literature and assure that the TuM1 
module was previously unreported. The identification of TuM1 as a novel module 
thus demonstrates the ability of the modular approach (ie, SA) to reveal new 
molecular patterns in genome-wide expression data.  
To further address the novelty of the TuM1, we ask whether TuM1 module 
can be simply detected by standard hierarchical clustering methods, especially 
given the fact that several groups have previously published extensive analyses of 
breast cancer expression data (8, 23, 25). We thus re-analyzed breast cancer 
expression data by using standard hierarchical clustering (7). We used a standard 
deviation (SD) filter to select the top 1,500 genes exhibiting the highest variation 
in expression among samples. This particular SD threshold was chosen to ensure 
the presence of sufficient TuM1 genes (~50%) in the filtered data. Average-
linkage hierarchical clustering employing a Pearson correlation metric was 
performed on this gene set. As expected, an ER-related gene cluster containing a 
large number of genes (~560) was identified. Other tumor modules like Stromal 
cells, ERBB2, Basal/ER-, immune and cell proliferation can also be identified by 
hierarchical clustering (Figure 3.4). However, TuM1 genes failed to form a 
uniform group that is distinct from other ER-related genes. In fact, some TuM1 
genes even failed to be clustered within the ER-related gene cluster (Figure 3.4). 
Similar results were obtained when the hierarchical clustering was performed on 
the global ISA-input gene set of 9116 probes, indicating the loss of TuM1 is 
unlikely due to the selection of top variant genes (data not shown). This result 
indicates that it would have been highly unlikely for TuM1 to be readily 
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discernible using conventional clustering approaches, supporting our hypothesis 
that novel biological information remains in these data sets despite their having 
received substantial prior analysis, which can be unearthed using alternative 
analytical methods such as SA. For the remainder of this report, we now focus on 
the novel TuM1 module in terms of its gene content, robustness, clinical 
associations and general applicability.   
 
 34 
Figure 3.4  TuM1 cluster is not readily detected by Hierarchical clustering  
A) Unsupervised clustering of breast cancer gene expression data. The top 1500 
most highly varying genes were selected using a simple standard deviation filter. 
This gene number was used to ensure that at least 50% of TuM1 genes were 
contained in the clustered gene set. Average-linkage hierarchical clustering 
employing a Pearson correlation metric was performed using CLUSTER software 
and displayed by TREEVIEW. 14 out of 16 TuM1 genes lay in the ER cluster; 
while the other two were outliers (yellow frame).  
B) Zoom-in of the ER gene cluster from Hierarchical Clustering. The TuM1 genes 
are highlighted. 
 
3.7 TuM1 is A Robust Module 
To test the identification of TuM1 is not simply by chance or dependent on the 
particular training set (ie, 96 breast tumors), we evaluated the robustness of TuM1 
using two data analysis strategies.  
First, we evaluated TuM1 in the independent set of 86 breast cancer 
tumors by using recurrence analysis, the method to assess the robustness of a 
module (see Figure 3.2). We found TuM1 remained as a highly recurrent co-
regulated module, as TuM1 remained as a tightly correlated gene cluster 
compared to random gene sets (Figure 3.5). Moreover, in this independent set 
TuM1 is also overexpressed in ER+ tumors.  
Second, we adopted a rigorous cross-validation strategy: repeated random 
sampling (43). We randomly generated one hundred sets of 96 tumors from the 
combination of 182 samples (96 in the training and 86 in the test set). Thus, there 
are 100 new ‘training set’ with the same sample size as the initial training set; 
each has different composition of tumor samples. The recurrence analysis method 
was used to evaluate TuM1 on all 100 random sampling training sets. We found 
that in >85% of cases TuM1 displayed substantially higher recurrence scores (ie, 
more robust) compared with random gene set (Figure 3.5). Random gene set is 
generated by randomly selecting 34 genes (same number of genes as TuM1) from 
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the whole 9,116 probe set. In the remaining 15%, the failure to observe TuM1 
could be attributed to the lack of TuM1-expressing tumors in the random set. We 
also independently repeated the entire ISA on a subset of these randomly 
generated sets, and confirmed that the TuM1 module could be rederived.  
These results show that the TuM1 module is indeed highly robust within 
our center, and later in this report we also show that the TuM1 module is also 
present in breast cancer expression data sets from other groups.  
 
Figure 3.5  Robustness of TuM1 
Left panel: Recurrence analysis of TuM1 on an independent set. TuM1 (blue line) 
shows a large number of highly overlapping outputs, compared to random genes 
(red line) which yield little or no overlap in output. The X axis (recurrence) 
represents the overlap between TuM1 and 20 derivation signatures, while the Y 
axis represents the percentage of derivation signatures under a certain recurrence 
level.  
Right panel: Recurrence analysis on random sampling validation (100 times). 
Each line represents one run of SA recurrence analysis. The recurrence of TuM1 
(blue lines) is much higher than by chance (red line – there are 100 red lines). In 
85% of the 100 random sampling validations, 70% or more of the derivation 
signatures showed > 50% recurrence with TuM1.  
 
3.8 TuM1 is an Apoptotic Tumor Module and Associated 
with Low Histologic Grade in an ER-independent Fashion  
We have demonstrated TuM1 is a robust co-regulated module. It is logically to 
hypothesize that TuM1 genes participate in one or several common cellular 
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functions or pathways since they are tightly co-regulated. To explore the 
functional role of TuM1, we used Ingenuity Pathway Analysis (IPA) 
(http://www.ingenuity.com/products/pathways_analysis.html), a commercial 
database for identifying networks and pathways of interest in genomic data which 
was also been used in several other published reports (44, 45). The IPA system 
utilizes a proprietary ontology representing over 300,000 classes of biological 
objects and semantically encoded relationships from the public domain literature 
to assign biological functions to a query data set (eg Affymetrix probes). The 
significance of functional enrichment is computed by a Fisher’s Exact Test, and 
represented by a range of p-values associated with either top level functions or 
related sub-functions. Using Ingenuity pathway analysis, we found that genes 
related to apoptosis and cell death were significantly enriched in the TuM1 
module (p-values = 1.66E-5 to 0.034), such as programmed cell death 4 
(PDCD4), mitochondrial ribosomal protein S30 (MRPS30) and gap junction 
protein, α1 (GJA1). Other genes in TuM1 include the xenobiotic-metabolizing 
enzymes NAT1 and FMO5, and PCM1, which was recently reported to be 
associated with histological grade in breast cancer (46). A fully annotated list of 
TuM1 genes is listed in the Appendix Table 3.8. This pathway analysis result 
suggests that the TuM1 module is likely to be biologically coherent and 
functionally significant. To investigate the clinical relevance of the TuMs we 
asked which clinical or histopathologic parameters are correlated with the TuMs’ 
expression. Every tumor module is associated with a set of tumors. The 
significance of each tumor is characterized by a score (the “tumor score”). A 
positive or negative score indicates that in this tumor the genes of the tumor 
module are upregulated or downregulated, in comparison to the rest of the tumor 
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population. In the present study, we have only studied tumors with positive scores 
because tumors with negative scores are very rare. These tumors were defined as 
TuM-expressed tumors. Chi-square tests were used to calculate the association 
between each TuM (TuM-expression tumors vs. others) and the following clinical 
parameters: patient age, lymph node (LN) status, estrogen receptor (ER) status, 
progesterone receptor (PR) status, tumor size, histological grade (as continuous 
variable), and lymphovascular invasion (LVI). The significance of each 
association was also confirmed by hypergeometric probability density function 
analysis. We observed significant correlations (p<0.05) between TuMs and 
various clinical variables. As expected, TuM1, 2 and 3, derived from a single ER-
relate gene module, are positively correlated with estrange receptor (ER) 
positivity and progesterone receptor (PR) positivity; while TuM6 and TuM8, 
representing the ER-/Basal and ERBB2+ molecular subtypes respectively, were 
significantly negatively correlated with ER and PR (Table 3.1). TuM7, the cell 
proliferation cluster, is significantly correlated with high histological grade but not 
correlated with ER status. 
TuM1 is also significantly correlated with low histological grade, smaller 
tumor size, less lymphovasular invasion; but not age and lymph node status (Table 
3.1). In general, TuM1 is overexpressed in breast tumors with less aggressiveness 
in the clinical behavior, consistent with our finding that TuM1 is a pro-apoptosis 
module. This result suggests that despite the unsupervised nature of the ISA, many 
of the TuMs identified by the SA are nevertheless associated with observable and 







Age Size  
   
 
 (≤/>55) (≤/>3 cm) Grade LN ER PR LVI 
TuM1 (Low Grade)  
0.0152  
(≤3*) <0.001   <0.001 (+) 0.0107 (+) 0.0152 (-) 
TuM2 (ER+/Luminal)   0.005  <0.001 (+) 0.0021 (+)  
TuM3 (ER+ II)     <0.001 (+) 0.0015 (+)  
TuM4 (Immune)     0.0044 (-)   
TuM5 (Stroma)        
TuM6 (ER-/Basal)    0.0236 (+) <0.001 (-) 0.0098 (-)  
TuM7 (Cell 
Proliferation)   <0.001     
TuM8 (ERBB2+)     <0.001 (-) <0.001 (-)  
Table 3.1  Correlations between TuMs and Clinical Characteristics  
*The variable inside the parentheses indicates the direction of correlations with 
TuMs 
Only association with statistical significance (P<0.05) are displayed. 
 
The observation that TuM1 and TuM2 were significantly correlated with 
both ER status and histologic grade made us consider if these associations were 
occurring independently of one another, or if these two clinical variables (ER and 
grade) were mutually related. ER status has been previously shown to be strongly 
associated with histological grade in breast cancer (47-52). Indeed, consistent with 
these previous reports, there is a clear correlation between ER and grade in all the 
data sets analyzed in this report; that is, most of ER-neg tumors have higher grade 
3 (Figure 3.6). Because of the strong association between ER status and grade, the 
correlation we observed between TuM1 & 2 and low grade might be due to the 
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Figure 3.6  The correlation of grade and ER status in multiple breast cancer 
data sets  
The dark blue line is grade; the pink line is ER status. Y-axis showed the grade (1-
3). ER-positive was assigned as 1 (Y-axis) and ER-negative was assigned as 0. 
The samples were sorted by ER, and by grade subsequently. 
 
To assess whether TuM1 is independently correlated with grade, we used 
multivariate analysis, a method based on the statistical principle of multivariate 
statistics, which involves observation and analysis of more than one statistical 
variable at a time. Linear regression analysis was used in the multivariate analysis 
to determine a linear formula that can describe how some variables respond to 
changes in others – that is, whether some variables are dependent on others. Using 
grade as an independent variable, we fed all eight TuMs and all other clinical 
variables (including ER) to the linear regression multivariate analysis. We found 
that TuM1 was significantly correlated with grade (p<0.001), but TuM2 was not 
correlated with grade (p=0.9) (Table 3.2). We also repeated the univariate 
association studies, this time using a sample set of only ER positive tumors (unlike 
the previous analysis where all tumors were used). In this “ER positive only” data 
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set, we found that TuM1 still remained significantly correlated with low tumor 
grade (p<0.001, Appendix Table 3.9). In contrast, TuM2 and TuM3, which both 
contain several ER-related genes, failed to exhibit a significant correlation with 
tumor grade when the ER negative tumors were removed from the analysis 
(p=0.16 and p=0.34 respectively). These results indicate that the TuM1 expression 
signature is significantly correlated with low histological grade in breast tumors, 
and that this association is independent of ER status. 
Variable P-Value Regression Coefficient  




 Lower Bound Upper Bound 
TuM1 <0.001 0.783 0.404 1.162 
TuM2 0.898 -0.025 -0.418 0.367 
TuM3 0.586 -0.111 -0.516 0.294 
TuM4 0.353 -0.125 -0.391 0.141 
TuM5 0.426 0.120 -0.179 0.420 
TuM6 0.405 0.127 -0.174 0.427 
TuM7 0.192 -0.184 -0.462 0.094 
TuM8 0.337 -0.137 -0.420 0.146 
AGE 0.197 0.006 -0.003 0.016 
SIZE 0.317 0.003 -0.003 0.009 
NODE 0.106 0.183 -0.040 0.406 
ER 0.091 -0.255 -0.551 0.041 
PR 0.020 0.315 0.052 0.579 
Table 3.2  Correlation between grade and TuMs and other clinical 
parameters in breast cancer  
The correlation is calculated by using linear regression multivariate analysis 
(SPSS). Besides TuM1, only PR is marginally correlated with grade. The positive 
regression coefficient means the variable is associated with low grade. 
 
3.9 Validation of Association between TuM1 Low 
Histologic Grade in Multiple Independent Test Sets 
We have established a novel, robust, biologically meaningful and clinical-relevant 
tumor module TuM1. We then test the general applicability of the TuM1 by 
validating it in an external series of patient populations. We tested a total of four 
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independent publicly available breast cancer data sets with grade status available, 
all utilizing different array platforms and patient selection criteria. The first (the 
“Rosetta data set”) consists of 117 breast tumors (71 ER+ tumors) profiled using 
oligonucleotide microarrays (12), the second (the “Stanford data set”) 122 breast 
tissue samples (81 ER+ tumors) profiled using cDNA microarrays (24), the third 
(the “Ma data set”) 60 ER+ tumors profiled using a separate cDNA microarray 
platform (31), and the fourth (the “Uppsala data set”) 67 ER+ tumors profiles on 
Affymetrix U133A arrays (53). 
We first test TuM1 is preserved in these data sets : 13 out of 33 TuM1 
genes in Stanford data, 21 genes in Rosetta, 21 genes in Ma and all 33 TuM1 
genes in Uppsala (which utilize the same microarray platform as our original 
cohort). As shown in latter, the smaller overlapping gene sets in the first three 
cohorts (Stanford, Rosetta, and Ma) are still sufficient to distinctly segregate the 
tumors into distinct groups on the basis of their overall expression ratios. To 
further show that the smaller overlapping gene sets are indeed sufficient to 
identify the TuM1 expression tumor population, we have now re-tested the 
overlapping gene sets used in the Rosetta, Stanford, and Ma data sets in our 
original tumor cohort, and confirmed that all three overlapping sets can 
successfully re-identified almost all 14 TuM1-associated tumors, in which TuM1 
genes are overexpressed. This result showed that these smaller subsets of TuM1 
can also function as accurate surrogates of the entire TuM1 tumor module.  
We then test whether the correlation between TuM1 and grade is valid in 
these four external test sets. As shown in Table 3.3, in all four independent data 
sets, the multivariate analysis showed that TuM1 is independently associated with 
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grade (Table 3.3). This was further confirmed by univariate analysis using ER 
positive tumor only. As shown in Table 3.4, the TuM1 expression signature 
divided the ER positive tumors into two distinct subgroups, with tumors 
expressing high levels of the TuM1 signature being significantly associated with 
low histologic grade. These results, consistent with the results from our own in-
house series, strongly suggest that the TuM1 expression signature is likely to be a 
robust, specific, and generally applicable molecular signature for low histologic 
grade in breast cancer, as it is observed in a variety of independent data sets 
associated derived from a wide variety of disease stages and patient populations 
and profiled using different array platforms. 
 
Ma P-Value Regression Coefficient 




  Lower Bound Upper Bound 
TuM1 0.015 0.395 0.082 0.707 
SIZE 0.497 0.045 -0.087 0.176 
NODE 0.929 0.013 -0.281 0.307 
AGE 0.704 0.003 -0.014 0.021 
Rosetta 
    
METAST 0.022 0.323 0.048 0.597 
TuM1 0.014 0.414 0.085 0.744 
ANGIOINV 0.197 0.178 -0.094 0.449 
ER 0.269 -0.003 -0.007 0.002 
LVI 0.242 0.209 -0.143 0.560 
AGE 0.859 -0.002 -0.021 0.017 
SIZE 0.138 0.012 -0.004 0.028 
PR 0.688 -0.001 -0.005 0.003 
Stanford   
 
TuM1 <0.001 0.499 0.230 0.768 
AGE 0.270 -0.005 -0.013 0.004 
SIZE 0.894 0.010 -0.143 0.163 
NODE 0.634 0.037 -0.116 0.190 
ER 0.119 -0.229 -0.518 0.060 
Uppsala 
  Lower Bound Upper Bound 
P53 0.008 0.469 0.126 0.812 
AGE 0.202 0.008 -0.004 0.021 
SIZE 0.100 0.012 -0.002 0.026 
TuM1 0.017 0.330 0.062 0.599 
Table 3.3  Multivariate analysis of associations between grade and TuM1, as 
well as various clinical characters 
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The independent significant association (p<0.05) is displayed in bold text. The 
positive regression coefficient means the variable is associated with low grade. 
 
 
Stanford Rosetta Ma Uppsala 
Grade 0.0002 <0.001 0.023 0.005 
1 6 3 3 9 3 0 7 5 
2 26 14 15 9 30 9 20 22 
3 6 26 3 33 8 10 0 12 
Table 3.4  Correlation between TuM1 and grade within ER+ tumors in four 
public data sets  
1st column of each data set represents TuM1 overexpressed tumors. 
 
3.10 TuM1 Module is Down-regulated Upon Tamoxifen 
Treatment In Vitro 
TuM1 is derived from a homogenous module that contains a large number of ER-
related genes. TuM1 is also overexpressed in a subset of ER+ tumors. These 
observations raise the possibility that the expression of TuM1 may intervene with 
ER activity and signaling. To investigate the relationship between TuM1 
expression and ER signaling, we decided to monitor the responsiveness of TuM1 
to ER activity using an in vitro system.  
First, we screened the expression of TuM1 across a set of breast and 
gastric cancer cell lines.  We profiled five breast cancer cell lines: MCF7 (ER+, 
HER2-), HCC38 (ER-, HER2-), BT474(ER+, HER2++), SKBR3(ER-, HER2++) 
and HCC202(ER-, HER2+). Seven gastric cell lines: AGS, SUN1, SUN5, SUN16, 
KatoIII, Hs746, N87 have also been included as a reference. All the cell lines 
were obtained from American Type Culture Collection center (Manassas, VA). 
Figure 3.7 showed that the overexpression of TuM1 genes is dominant in MCF7 
cell line, which is a well-known ER+ breast cancer cell lines. This result showed 
that in in vitro cell line system TuM1 is also overexpressed in ER+ caner cells.  
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Figure 3.7  Hierarchical clustering of various cell lines on the basis of 
expression profiling of TuM1 genes 
Average-linkage hierarchical clustering employing a Pearson correlation metric 
was used in this analysis. The overexpression of TuM1 genes in MCF7 is 
highlighted in a yellow rectangle. Red color indicates higher expression levels and 
green color indicates lower expression levels. Grey color indicates the expression 
of a particular gene cannot be detected (ie, missing value).  
 
Second, we treated MCF7 cells with tamoxifen, a selective estrogen 
receptor modulator (SERM) that compete with estrogen in the body for binding to 
the estrogen receptor and act as an antagonist to inhibit the transcription of 
estrogen-responsive genes. Before tamoxifen treatment, cells were washed three 
times in PBS and maintained in phenol red free DMEM with 5% Dextran 
charcoal-stripped FBS (HyClone Laboratories, Pittsburgh, PA) for 24 hrs. 
Subsequently cells were treated with 10 µM tamoxifen (Sigma) and harvested at 
48 hrs. Control sister cultures were treated with an equivalent volume of the 
vehicle (0.1% ethanol). The expression profiling of MCF-7 cell lines was 
performed in duplicate from two independent sets of RNA samples each 
comprising control untreated MCF7 cells, cells treated with 10 µM Tamoxifen for 
48 hrs, and cells treated with vehicle (0.1% ethanol) for 48 hrs. The expression 
profiling of MCF-7 was performed on HG-U133 plus gene chips. 
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 We then compared the expression of TuM1 in before- and after- 
tamoxifen treated cells. In order to test the TuM1as a uniform gene set, rather than 
multiple individual genes, we used Gene Set Enrichment Analysis (GSEA). GSEA 
is a modification of the weighted Kolmogorov-Smirnov (KS) statistic and 
provides a general statistical framework to test for the enrichment of gene 
expression profiles (54). GSEA considers a priori defined gene set, such as co-
regulated genes, and determines whether these members are enriched at the top (or 
bottom) of a list of markers ranked by the degree of correlation with a specific 
class distinction (ie, control vs. treated). Multiple hypothesis testing is adjusted by 
calculating false discovery rate (FDR) (54). The FDR is the estimated probability 
that the reported result is false positive. We queried each of the eight TuMs into 
the gene list ranked by their correlation with the class distinction between control 
and treated MCF7 cells. Using GSEA we found that TuM1 is the only tumor 
module that is significantly downregulated in tamoxifen-treated MCF7 cells 
compared to controls (Table 3.5). As a contrast, the expression of other tumor 
modules are either not expressed in ER+ cell lines or not affected by tamoxifen 
treatment. TuM2, which contains estrogen receptor gene (ESR1), was marginally 
correlated with tamoxifen treatment. This result suggests that at least in vitro, 
TuM1 expression may be dependent on active ER signaling, and may thus 
represent a ‘molecular signature’ of ER activity. 
Table 3.5  GSEA of TuM1 in tamoxifen-treated MCF7 cell line vs. control. 
NAME SIZE ES NES NOM p-val FDR q-val FWER p-val 
downregulated in treated MCF7 cells    
TuM1 16 0.616471 1.6929 0 0.05 0 
TuM2 16 0.727534 1.426171 0 0.19 0.15 
TuM7 33 0.797655 1.320043 0.159574 0.216667 0.37 
TuM3 10 0.588948 1.24243 0.146341 0.266667 0.45 
       
upregulated in treated MCF7 cells    
TuM8 25 -0.51 -1.18 0.429 0.34 0.38 
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Three modules (TuM4, 5 and 6) were filtered out due to insufficient number of 
genes (<10) expressed in MCF7 cell lines. TuM1 is the only module showed a 
significant correlation with control samples (ie, downregulated in treated MCF7 
cell line) 
 
3.11 TuM1 Member Gene relaxin 2 Mediates Tamoxifen 
Response in MCF7 Cell Line 
ER signaling is a complex pathway that cross-link to many other pathways. The 
disruption of ER signaling pathway may affect many other genes that may not 
necessarily be functionally involved in the tamoxifen response of ER+ breast 
cancer cells. To explore whether TuM1 is functionally involved in the tamoxifen 
response, we used siRNA to knock down relaxin 2 (RLN2), one of the TuM1 
gene, to see whether TuM1 gene is crucial for tamoxifen response. RLN2 is one of 
the top genes whose expression is significantly altered upon tamoxifen treatment. 
siRNA efficiently repress the expression of RLN2 in MCF7 cell line (Figure 3.8). 
We then treated the RLN2 knock-down MCF7 cell line with tamoxifen. As a 
control, we treated MCF7 with non-specific control-siRNA and subsequently 
tamoxifen. As shown in Figure 3.8, the repression of RLN2 greatly reduced the 
tamoxifen-induced apoptosis. This result suggested that the TuM1 gene, at least 





Figure 3.8  Tamoxifen treatment on RLN2 knock-down MCF7 cell line  
Top panel: siRNA knock down of RLN2 in MCF7 cell line. RT-PCR figure 
showed silencing of RLN2 gene in MCF7 cells. β-Actin was used as the internal 
control.  
Middle panel: Representative Photographs of MCF7 cells in the apoptosis assay. 
Four panels depict (from left to right):  control siRNA + vehicle; RLN2 siRNA + 
vehicle; control siRNA + tamoxien; RLN2 siRNA + tamoxifen. 
Bottom panel: Percentage of apoptosis cells was scored and plotted.  
 
 
3.12 A Correlation between TuM1 Expression and Clinical 
Outcome of ER+ Patients 
Tamoxifen is a standard anti-hormonal therapy used to treat ER+ breast cancer 
patients (55). Our finding that expression of the TuM1 mediate tamoxifen 
response in ER+ breast cancer cells made us investigate if the presence of this 
module in primary tumors might function as a molecular biomarker to identify 
tumors that are likely to respond to tamoxifen or other anti-hormonal treatments. 
As clinical follow-up information was not available in our in-house data, we 
tested three independent data sets where ER+ patients have been treated with 
tamoxifen and the follow-up data is available:  
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a) First, we tested the Stanford series, which contains 81 patients who received 
adjuvant endocrine therapy if their tumors were ER+ (24). Using Kaplan-
Meier (KM) survival analysis, patients with TuM1-expressing ER+ tumors 
exhibited better survival outcomes compared to patients with ER+ tumors 
where TuM1 was not expressed (p=0.0001 for overall survival; p=0.0036 for 
relapse-free survival, Figure 3.9). In a multivariate analysis of TuM1, grade, 
age, lymph node and tumor size, TuM1 behaved as an independent predictor 
of survival outcome, while grade did not, demonstrating that TuM1 is more 
directly prognostic of patient survival than grade status alone (Table 3.6).  
b) Second, we tested the Ma data set, which comprises a set of pre-selected 
tamoxifen responsive and resistant ER+ tumors (31). Once again, TuM1-
ovexpressing patients exhibited significantly better outcome than low TuM1 
patients (p=0.048, Figure 3.9). By multivariate Cox regression analysis, TuM1 
was the sole independent prognosis factor (p=0.03; Table 3.6); as grade, tumor 
size, node and age are controlled in the Ma patient cohort (31). This 
observation was also tested using Gene Set Enrichment Analysis (GSEA) 
which confirmed that TuM1 expression was significantly associated with 
tamoxifen response (p=0.024).  
c) Third, the prognostic ability of TuM1 was tested on the Uppsala set, an 
independent patient cohort of sixty-seven ER+ patients who received 
tamoxifen as monotherapy (53). Once again, patients with TuM1 expressing 
tumors experienced significantly improved overall survival outcomes 
compared to low TuM1-expressing patients (p=0.025, Figure 3.9). By 
multivariate Cox regression analysis, TuM1 remained significantly associated 
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with survival (p=0.024); while grade, tumor size, and lymph node status did 
not (Table 3.6).  
Taken collectively, these preliminary results raise the possibility that TuM1 
expression in primary tumors might also be associated with a tumor’s response to 
clinical treatment, in particular anti-hormonal therapy.  
 
Figure 3.9  Analysis of TuM1--disease outcome associations in three 
independent patient groups that received anti-hormonal treatment 
The figure is plotted using Kaplan-Meier analysis: A) Stanford data set: Overall 
survival for 81 ER+ patients, who received adjuvant endocrine treatment (5). B) 
Ma data set: metastasis-free survival for 60 ER+ patients receiving tamoxifen 
monotherapy (28). C) Uppsala data set: Overall survival for 67 ER+ patients 
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Table 3.6  Multivariate analysis of TuM1--disease outcome 
The end-point of survival follow-up is death (Uppsala and Stanford) or metastasis 
(Ma) as the first event. Parameters found to be significant (P<0.05) in the COX 
proportional hazard model are shown in bold. 
 
3.13 A Prospective Clinical Validation of TuM1 Using a 
Customized microarray 
In a separate study, we fabricated custom 188-gene microarrays containing six 
expression signatures for breast cancer identified by our group (19, 25, 56, 57). 
The reliability of these multiple signature arrays (MSAs) was tested in a 
prospective cohort of 163 non-metastatic primary breast cancer samples from 
2000-2003 were obtained from the National Cancer Centre of Singapore (NCCS) 
Tissue Repository. TuM1 was included in this clinical validation study. We 
validated the correlation between TuM1 and grade in this 89 Luminal/ER+ tumor 
cohort. Forty-five out of 89 luminal/ER+ cases (51%) were classified as 
expressing high-levels of the TuM1 expression signature, while 44 cases were 
classified as TuM1 negative. A comparison with histologic grade revealed that 15 
of 17 grade 1 tumors (88%) exhibited high levels of TuM1 expression compared 
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to 30 of 72 grade 2 and 3 tumors (p=0.002, Fisher’s exact test). These figures are 
consistent with our findings, and validate the association between TuM1 
expression and tumor grade. 
Most of ER+ patients received tamoxifen treatment. Hence we also looked 
at the relationship between TuM1 and survival outcome in this ER+ patient 
cohort. By using univariate Kaplan-Meier (KM) survival analysis, we found that 
TuM1 is significantly correlated with disease free survival (p=0.01, Figure 3.10). 
The multivariate COX regression analysis showed that only TuM1 (p=0.019) 
remained as an independent prognosis factor; while tumor size, tumor stage, 
lymph node status, histological grade, and lymphovascular invasion are not. 
Notably, the use of adjuvant chemotherapy (HR=0.7, p=0.225) in this cohort did 
not significantly affect disease free survival. As patients in this validation set who 
had ER+ tumors were the recipients of anti-hormonal therapy, this result is 
consistent with our initial hypothesis that TuM1 may predict response to anti-
hormonal therapy. In this study clinical follow-up is still in the early years and 
immature, and hence the long-term prognostic power of some signatures cannot be 
conclusively assessed. Nevertheless, TuM1 was associated with improved 
survival, even in this interim analysis.  
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Figure 3.10  TuM1—Disease outcome of 89 ER+ patients in a prospective 
study 
High expression of TuM1 is represented by the orange line and low expression of 
TuM1 by the green line. The hazard ratio (HR) of high TuM1 to low TuM1 and 
P-values was calculated using the Cox-regression, with stepwise forward 
hierarchical selection in the multivariate analysis. 
 
3.14 Summary 
microarray-based gene expression profiling has been used extensively in cancer 
research. The complex genetic and molecular heterogeneity of cancer made the 
discovery of a robust molecular signature remain as a challenging task. Recently, 
the conventional mathematic-oriented algorithms, which are popular deployed in 
microarray studies, have been revealed with certain limitations (see Chapter 1.4). 
Furthermore, it has been proposed that the comprehensive identification of gene 
signatures representing specific biological mechanisms and pathways (“bottom-
up” approach) can edge over conventional classification methods (“top-down” 
approach) (58). To achieve this aim, a number of powerful ‘modular’ tools, such 
as SA and others have been developed, which are capable of identifying sets of 
genes associated with specific functions that are conditionally co-regulated in 
tumors. In this report, we applied SA to characterize a set of breast tumor 
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expression profiles, and identified a novel cell death and apoptosis related gene 
expression signature (TuM1) that was not readily discernible using conventional 
clustering approaches. Notably, these analyses were all performed on breast 
cancer data sets that had previously been extensively analyzed by multiple groups 
(8, 12, 23-25) - the successful identification of TuM1 as a novel module thus 
highlights the richness of information that likely remains embedded in such 
genome-wide data and awaiting discovery. We further found that the TuM1 
module was highly robust across multiple independent data sets, and was 
significantly enriched in genes associated with cell death and apoptosis, 
supportive of its biological coherence. Taken collectively, these results 
demonstrate that module-based approaches can successfully identify novel, robust 
and biologically meaningful gene signatures in breast cancer. 
In conclusion, our result demonstrates the feasibility and utility of 
applying modular analytical approaches such as SA on cancer expression data. 
Besides breast cancer, our results suggest that, with the increasing availability of 
larger and comprehensive expression data sets, sophisticated analytical tools such 
as SA may be useful in refining our global understanding of the gene expression 
pathways in various malignancies. 
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Chapter 4. A Precisely Regulated Gene Expression 
Cassette Potently Modulates Metastasis and 
Survival in Multiple Solid Cancers 
 
4.1 Precise Regulation and Ultrasensitivity 
The precise regulation and integration of signal flow is a common feature of many 
biological networks ranging from normal physiologic processes to complex 
disease states. As illustrated by the examples of oxygen handling (59) to energy 
control (60), and ionic homeostasis (61), achieving precision frequently involves 
the coordinated deployment of multiple distinct cellular pathways and 
mechanisms for balancing opposing activities. In cancer network, similar 
requirements for pathway balance also occurs, where successful tumorigenesis 
entails the integration of multiple pro- and anti-oncogenic pathways controlling 
cellular proliferation, apoptosis, motility, adhesion and senescence (62, 63). For 
instance, both overexpression and depletion of HEF1, a proposed ‘hub’ gene for 
cancer metastasis (64),  cause mitotic defects in cultured cells (65, 66). Similarly, 
subtle alterations of HMMR, gene involved in centrosome formation (67),  
expression in normal mammary tissues may promote breast tumorigenesis, 
underscoring the need to keep the HMMR gene tightly regulated (67).  Such 
findings support the notion that balancing the activity of positive and negative 
effectors is likely to be a central requirement observed in many cancers.  
To ensure this precise balance (68), biological networks have developed a 
variety of systems-level mechanisms, such as feedback control, inter-pathway 
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cross-talk, and signal amplification (17, 18, 69, 70). However, the pivotal 
balancing role played by certain genetic components may at least partially explain 
why some networks also exhibit ultrasensitivity, where very small changes in 
stimuli can suffice to elicit qualitative changes in output (17). The presence of 
ultrasensitive components has been proposed to contribute to a system’s ability to 
rapidly respond to changing environmental and genetic conditions (71, 72). 
Recent reports have suggested the existence of ultrasensitive components in 
cancer, one remarkable example being the dramatic responses of chronic 
lymphocytic leukemia cells to colchicines, occurring at concentrations 10,000-fold 
lower than that required for similar effects on normal lymphocytes (73), and the 
striking clinical responses of certain solid tumors to targeted pathway inhibitors 
(74). From a therapeutic perspective, such components might also prove 
particularly appealing as drug targets, since even small alterations might prove 
sufficient to induce potent effects on tumor phenotypes. However, our current 
understanding of the role that ultrasensitivity plays in cancer is still far from 
complete. Identifying additional genetic components regulating pathway balance 
in tumors might thus improve our ability to target critical control nodes in cancer 
networks. 
As a general strategy to identify ultrasensitive components of precise 
regulation system in tumors, we hypothesized that a) such genes should be 
precisely regulated, and thus exhibit restricted levels of transcriptional variation in 
cancers; and b) subtle alterations in the expression levels of these genes should 
induce or be associated with significant phenotypic changes. We expect the 
following observations: 1) the phenomenon of precise regulation should be 
cancer-specific; 2) such precise regulation should be observed (validated) in 
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multiple cancer data sets; 3) the genes under this cancer-specific precise 
regulation are functionally relevant to tumorigenesis; 4) the subtle alterations on 
these ultrasensitive components will induce the drastic perturbation on the cellular 
behavior of cancer cells; 5) such subtle variation of these ultrasensitive 
components in primary tumors may be also associated with clinical outcomes as 
the influence of subtle variation on tumor cells is significant. We will address 
these predictions in the following sections.   
 
 
4.2 Gene Expression Analysis to Identify Ultrasensitive 
Components  
microarray Data Analysis, especially supervised learning methods, mainly focus 
on ‘differentially expressed genes’, which are significantly over- or under-
expressed in one phenotype, compared to other phenotypes. Phenotypes here can 
be referred to cancer and normal. These approaches lead to the identification of 
‘activate’ (ie, expressed) genes under a particular phenotype. While looking at the 
absolute expression level is important, these methods ignore the scale of 
expression variation. As we hypothesized, the restricted window of expression 
level (ie, the small expression variation) may reflect the important biological 
phenomenon – precise regulation system. Hence the analysis on expression 
variation may reveal novel biological regulation mechanism. 
While several groups have compared the expression profiles of tumor and 
non-malignant tissues (75, 76), to our knowledge, no study to date has 
systematically attempted to investigate the issue of precise gene regulation. The 
focus on the expression variation have been driven by the attempt to define 
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‘housekeeping’ genes that are stably and ubiquitously expressed in multiple 
tissues and conditions, and therefore these genes can be used as internal controls 
and normalization standards for a variety of biological experiments. 
We hypothesized that some genes exhibited subtle yet important 
expression variation in cancers. We then applied these parameters to determine if 
such genes might be inferred from databases of tumor gene expression profiles. 
Employing a novel genome-wide computational strategy, we identified and 
robustly validated a novel “Poised Gene Cassette” (PGC) of genes exhibiting 
precise regulation in a microarray database of human tumors from diverse tissue 
types. We then demonstrated that subtle alterations in PGC expression are 
associated with significant and measurable alterations in important tumor 
phenotypes such as experimental metastasis and patient survival. Finally, we show 
that conventional microarray analysis algorithms would have failed to detect the 
majority of PGC genes, perhaps explaining in part why they may have been 
missed in previous studies. Our results thus suggest the existence of a generalized 
homeostatic mechanism in solid tumors for maintaining precise levels of PGC 
transcription, which may be important for various cancer-associated phenotypes, 
such as tissue invasion and metastasis. Importantly, the approach described in this 
study is quite generalizable and not limited to cancer. 
 
4.3 A Conserved Cassette of Precisely Regulated Gene 
Expression in Multiple Solid Tumors 
To investigate the gene expression variation in multiple tumor gene expression 
profiles, we generated gene expression profiles for 270 primary tumors from six 
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tissue types (breast, colon, liver, lung, oesophageal and thyroid) using Affymetrix 
U133A Genechips (Table 4.1). To identify genes whose precise regulation was 
tumor-specific, we generated a second database of 71 adjacent matched normal 
tissues (“control” tissues) to eliminate genes that were also tightly regulated in 
non-malignant samples. These samples obtained from the Tissue Repository of the 
National Cancer Centre of Singapore (NCCS). Institutional approvals were 
obtained from the NCCS Tissue Repository and Ethics Committees. In the 
operating theater, morphologically visible tumor and adjacent matched normal 
tissues were removed by surgery and examined by a surgical pathologist to 
confirm the presence of cancer cells by cryosections. The tissue samples were 
divided into discrete aliquots, flash frozen and subsequently stored in liquid 
nitrogen. RNA was extracted from the tissues using Trizol reagent (Invitrogen, 
Carlsbad, CA) and processed for microarray hybridizations on Affymetrix U133A 
Genechips according to the manufacturer's instructions (Affymetrix Inc., Santa 
Clara, CA). The expression data has been deposited into the Gene Expression 
Omnibus (GEO) database (GSE5364). GEO is an online curated database for 
microarray data deposit, browsing, query and retrieval 
(http://www.ncbi.nlm.nih.gov/geo/). 
Tissue Type Tumor Control 
Lung 18 12 
Thyroid 35 16 
Liver 9 8 
Oesophagus 16 13 
Colon 9 9 
Breast 183 13 
Total 270 71 
Table 4.1  Summary of samples used in the training data set to define PGC.  
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Raw Genechip scans were processed using the MAS 5.0 algorithm 
(Affymetrix) normalized by median-centering (GeneData, Basel, Switzerland). In 
addition to expression summaries, the MAS 5.0 also generates a p-score that 
assesses the reliability of each expression level. This is produced by using a 
signed rank test to consider the significance of the difference between the PM 
(perfect match) and MM (mismatch) values for each probe set. This value is 
referred to as the 'detection p-value', and is subsequently used to generate a 
'detection call', which flags the transcript as 'Present', 'Marginal' or 'Absent' 
(P/M/A). As proposed by the manufacturer, we used detection calls to filter out 
unreliable probe sets. We discarded probes with < 80% valid values (P-call < 
80%) across the training set samples. In section 4.4 we will discuss whether the 
alterative algorithms to generate expression data will affect our findings. For 
genes with multiple probes, we selected the best-match probes (to targets) 
represented by a “_at” extension. For genes with multiple “_at” extension probes, 
the probe with the highest P-call rate (ie, the highest valid value proportion) was 
used. The final pre-processed training set comprises 5729 unique genes, each 
represented by a single probe.  
Gene expression CVs (standard deviation divided by the mean expression 
level) were used to compute the variability of expression. For every gene, we 
computed gene expression coefficient of variances (CV), where genes with small 
CVs are considered more tightly regulated than genes with large CVs. At an 
empirical CV cut-off of <0.28 (CVT), 16% of genes in tumors were considered 
tightly regulated. The use of an absolute CV threshold for these filtering steps is 
permissible, as the global distribution of expression CVs between tumors and 
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controls were highly similar (mean CVs were 0.46 and 0.45 for tumors and 
controls) (Fig. 4.1A). 
To select genes that are only tightly regulated in tumors, we use the 
following parameters:  the genes have smaller expression variation in tumor: 
CV(tumor)<0.28 (CVT); while in normal their expression variation is distinctly 
apart from CV cut-off (CV>0.3; CVT+gap) where a ‘gap’ was introduced to 
enhance differences between tumors and control. Using this criterion, we 
identified a “Poised Gene Cassette” (PGC) of 48 genes exhibiting highly restricted 
levels of expression variation in tumors. The F-test, a statistical method for 
comparing the significance of difference in variation between data sets, confirmed 
that each of the 48 PGC genes was indeed associated with significantly decreased 
expression variation in tumors relative to controls (Fig. 4.1B, F-test) The PGC 
could be re-identified even after varying the CV threshold between 0.26-0.3 (+/-
7%), indicating that the identification of PGC is not vulnerable to a particular CV 
threshold (Appendix Table 4.6). 
 
Figure 4.1  Gene Expression Variation in tumor and non-malignant samples 
A) Distribution of gene expression variation (CV) in tissue samples. Equal 
numbers of tumors and control samples (50) were randomly selected from the 
training set to generate a cumulative distribution graph depicting the genome-wide 
distribution of CVs across tumors (red line) and controls (green line). Genes to the 
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left of the distribution curve correspond to genes with decreased CV (stably 
expressed), while genes on the right are associated with increased CV. The 
threshold CVΤ  of 0.28 (black dotted line) represents the value of CV where ~16% 
of genes in tumor samples are considered to be stably expressed (ie, CV<CVΤ, see 
Main Text for details).  
B) Expression variation of individual PGC genes in tumors and non-malignant 
samples. The height of the bar chart represents each gene’s mean expression level 
(in log scale), while the error bars (red lines) represent 2 standard deviations of 
expression values. PGC genes show significantly restricted variation in tumors. P-
values indicate the statistical significance of difference in expression variation (F-
Test). Note that the mean expression levels of these PGC genes are similar 
between tumors and non-malignant tissues.   
 
4.4 Identification of PGC is NOT due to the Artifact of 
microarray Data Analysis 
We investigated whether the reduced expression variation of the PGC might be 
due to technical features of the Affymetrix platform or our initial training set.  
First, we considered the possibility that the reduced variance of the PGC 
might be due to an overabundance of ‘poor quality’ probes, which might cross 
hybridize with multiple genes and hence generate higher background signals (77). 
However, an examination of a vendor provided list of questionable probes (ie, 
with ‘_s_at’ and ‘_x_at’  suffixes) (p=0.4; hypergeomtric distribution test), as well 
as an in-house list of unreliable array probes based on sequence redundancy and 
repeat mapping, confirmed that the PGC was not significantly enriched in poor 
quality probes (p=0.8; hypergeomtric distribution test).  
Second, to investigate the influence of normalization protocol on PGC 
discovery, we re-processed the training set using a different algorithm to generate 
expression summary data (RMA, (78, 79)). MAS 5.0 algorithm has been criticized 
for exaggerating variance in low abundance transcripts. It has been argued that 
which method is better for processing microarray data from Affymetrix. 
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Nevertheless, here we simply want to demonstrate both methods will lead to the 
discovery of PGC – genes which showed smaller expression variation in tumors, 
compared to control.  Indeed, in the RMA-normalized data, 90% of the original 
PGC genes still exhibited decreased expression variation in tumors relative to 
controls (ie, CV(control)>CV(tumors)) (Figure 4.2A). Thus, the tumor-specific 
expression stability of the PGC does not appear to be dependent upon a specific 
normalization technique.  
 
Figure 4.2  Validation of the PGC  
A) CV of PGC genes in RMA-processed data. Y-axis is the ratio for 
CV(tumor)/CV(control). Each bar represents a PGC gene. Red bar represent PGC 
genes with ratio less than 1, indicating the expression variation in tumor is smaller 
than in controls. Blue bar represent PGC genes with ratio greater than 1. 
B) Distribution of absolute expression levels for individual PGC genes. For each 
gene, the X-axis represents its expression level in tumors and the Y-axis its 
expression in non-malignant tissues. The PGC genes (black spots in the top panel) 
located around the diagonal line (ie, expression ratio of control/tumor = 1) and 
randomly scattered across the whole 5729-gene set (gray spots). 
 
Third, to ask if the reduced variation of the PGC might be due to the PGC 
genes being highly expressed in tumors, we compared the expression levels of the 
PGC genes against all genes in the microarray dataset. We found that the PGC 
genes were equally distributed across a wide range of expression levels and not 
confined to either low or highly expressing genes in either tumors or control 
tissues (Figure 4.2B). Thus, the reduced expression variation of the PGC in 
cancers is unlikely to be simply due to PGC genes being highly expressed in 
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tumors, in contrast to some studies suggesting that an inverse correlation between 
expression variation and absolute expression levels (80). It is also important to 
note that the PGC genes do not exhibit significant differences in their absolute 
mean expression levels between cancers and normal tissues (Figures 4.1B and 
4.2B), but instead only differ in their levels of expression variation between 
cancers and normal tissues. This observation, as well as others, also provides an 
argument that the PGC genes are unlikely to represent tissue-specific expression 
(see Discussion).  
 
Fourth, to investigate if discovery of the PGC might have been influenced 
by the overrepresentation of breast tumors in our initial training set (breast tumors 
comprised 68% of the training set; Table 4.1), we removed all the breast tissues 
and repeated the PGC analysis. Even without inclusion of breast tissues, 83% 
(40/48) of the PGC genes still exhibited reduced variation in tumors compared to 
controls. Of 47 genes exhibiting tumor-specific tight regulation in the breast-
excluded data (CV<0.28), 24 genes were part of the original PGC, an overlap far 
beyond random chance (50%, p=1.3E-11, hypergeometric test). Taken 
collectively, these results suggest that the identification of the PGC, and its 
restricted expression variation in cancers, is unlikely to be due to a technical 
artifact or specific-cancer type.  
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4.5 Failure of PGC Detection by Conventional microarray 
Analysis Methods 
The previous gene expression studies comparing tumors and non-malignant 
tissues have typically employed conventional microarray analysis algorithms such 
as t-tests with false positive correction (75) or SAM (81). Since genes detected by 
such techniques typically require both differing mean expression levels and 
equivalent levels of variation between the two cellular states (Figure 4.3), we 
hypothesized that PGC genes might not be detected by such conventional 
techniques. For example, PGC genes might not exhibit distinct mean expression 
levels between the two groups and only be associated with differing degrees of 
expression variation between tumors and controls (Figure 4.3). Indeed, performing 
SAM and t-tests on the training set only identified 27% of the original PGC, after 
multiple hypothesis correction, while the absolute mean expression levels of many 
PGC genes between tumors or non-malignant tissues were highly similar (Figure 
4.3). To ask if the unequal distributions in expression variation might underlie the 
failure of the PGC genes to be identified by conventional techniques, we also 
analyzed the original training data set using Welch’s test, an adaptation of 
Student's t-test intended for use with two groups having unequal variance. Again, 
75% of the PGC genes failed to be detected as significant using Welch’s test (data 
not shown). Also, a standard practice in microarray data process is to filter our 
genes exhibiting low variation, especially prior to clustering or statistical analysis. 
This variation filtering will inevitably lead a bias towards differentially expressed 
genes and prevent the discovery of PGC. Furthermore, it has been recently 
suggested that low variation genes may not contribute to higher false discovery 
rate (82). These findings suggest that conventional algorithms would likely have 
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failed to detect the PGC, indicating that studying expression variation may 
represent a useful alternative method for identifying novel genes relevant to 
disease biology.   
 




A) Example of a gene with differential absolute expression in distinct conditions. 
The mean expression level is greater in phenotype 1 (blue) compared to phenotype 
2 (red), but the mean expression variation (CV) being the same in both conditions. 
The Y-axis depicts an arbitrary range of expression values.  
B) Example of a gene with differential gene expression variation in different 
phenotypes. The expression variation is lower in phenotype 1 compared to 
phenotype 2, despite the ean expression level being similar in both conditions. The 
frequency histogram of expression values (right panel) demonstrates that the 
distribution of expression values in phenotype 2 is narrower than in phenotype 1.  
 C) Student’s t-test on the PGC: PGC were grouped into two categories based on 
their significance of t-test (p<0.05 for red spots; and p>0.05 for blue spots), after 
correction for multiple hypotheses using the Benjamini-Hochberg algorithm. The 
PGC genes were plotted based on the expression level in tumors (X-axis) and in 
controls (Y-axis). 
 
4.6 A Cross-Validation Assay Confirms Specificity and 
Robustness of the PGC Signature  
To confirm that the restricted expression variation of the PGC was specifically 
associated with malignancy, we determined the frequency at which a member 
gene of the PGC could be re-identified in a series of class-permutation tests. When 
the class labels of the samples (ie, tumor or control) were shuffled to generate a 
series of 1000 permuted sets, we found almost all the PGC genes (46/48, 96%) 
could only be re-identified in less than 5% of the class-permuted signatures, 
consistent with the decreased expression variation of the PGC being tightly 
associated with tumor samples.  
We then evaluated the robustness of the PGC by repeated random 
sampling (RSS), a stringent cross-validation strategy (43). The original training 
set was randomly divided 1000 times into two parts, generating a large series of 
distinct training/test set combinations. For each of the 1000 derived RSS training 
sets, we identified new PGC signatures (rPGC) and compared them to the original 
PGC gene set (Figure 4.4). Following the guidelines of Michels et al (43), 20 
genes were repeatedly selected in more than half of the 1,000 new rPGC 
 67 
signatures. Of these 20 genes, 19 (95%) are members of the original 48-gene PGC 
(Fig. 4.5) – the observation that only one gene that was not part of the original 
PGC signature was repeatedly selected in the RSS assay indicates that a 
substantial proportion of the PGC signature is robust to training set selection.  
 
Figure 4.4  workflow of repeated random sampling (RSS) 
Left Panel: identification rPGC signature using training set that is randomly 
selected from the original training set.  
Right Panel: validate the rPGC signatures in the matched test set.  
 
To evaluate the transportability of the PGC signatures, we then applied 
each of the 1000 rPGC signatures to their cognate test sets (Figure 4.4). Since 
most independent test sets are likely to contain either tumor or control samples but 
not both, we considered the tumors and controls separately from one another in 
this analysis. We then tested whether the RSS signatures (rPGC) were tightly 
regulated in the RSS test sets (tumor or control). First, we identified genes 
exhibiting similar restricted expression variation in the test data set, using the CVT 
threshold cut-off (CV(Test) < CVT). Second, we determined the overlap between 
the RSS gene signatures (rPGC) and the population of genes that were tightly 
regulated in the RSS test set. The hypergeometric distribution test was used to 
calculate the significance of the overlap. Significance was defined as p-value 
(p<0.01). As shown in Figure 4.5, the rPGC signatures were tightly regulated in 
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80% of the tumor test sets (PGCT), and importantly were NOT tightly-
regulated in 100% of the control test sets (PGCN), indicating that the PGC is 
robust in recapitulating its precise regulation in multiple tumor data sets, but not 




Figure 4.5  Cross-Validation of PGC by Repeated Random Sampling 
Left Panel: Genes belonging to the original PGC signature (blue lines) that were 
re-identified in at least 500 of 1,000 re-sampled rPGC signatures. The red bar 
represents the only gene (KHDRBS1) not belonging to the original PGC signature 
that was re-selected to the same frequency (ie >50%).  
Right Panel: Stability of re-selected PGC signatures in 1,000 cross-validation test 
sets. PGC was queried against either the set of tumor (blue line) or non-malignant 
tissues (red line) in the cognate cross-validation test set, PGCT in the figure 
indicates the PGC Tumortest comparison. Y-axis represented the statistical 
significance of overlap between any particular signature and the cohort of stably 
expressed genes in the tumor and non-malignant test sets (assessed by the 
hypergeometric distribution, with p-values of p<0.01 (dotted line) being deemed 
significant).   
 
4.7 Independent Validation of the PGC in Diverse Solid 
Tumors 
The precision of PGC regulation in cancer was repeatedly observed in 
independent data sets. We collected nine independent cancer cohorts, comprising 
in total 1105 tumor samples from >7 cancer types, including four tissues not 
represented in the original training data (gliomas, gastric, NPC, and ovarian). 
These include I) an in-house set of combination of 53 gastric tumors and 46 
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nasopharyngeal carcinomas (Yu_Gastric&NPC); II) a cohort of 286 lymph-node-
negative breast cancer patients (Wang_Breast data set; GEO accession number: 
GSE2034)  (44); III) 189 invasive breast carcinomas from two research 
institutions (Sotiriou_Breast data set; GSE2990) (83); IV) 125 ovarian tumors 
(Bild_Ovarian; GSE3149) (36); V) 118 lung tumors (Bild_Lung; GSE3141) (36); 
VI) 77 brain tumors (Phillips_Glimo; GSE4270) (84); VII) 100 colon tumors 
(Aronow_Colon; GSE5206); VIII) a collection of 60 cancer cell lines (NCI60, 
http://symatlas.gnf.org/SymAtlas/); and VIIII) a separate collection of 51 breast 
cancer cell lines (Neve_BCL) (85). Detailed descriptions of each data set are 
















#Samples 99 286 189 125 118 





olon NCI-60 Neve_BCL Total 
#Samples 77 100 60 51 1105 
Source GSE4270 GSE5206 SymAtlas 
Supplemen
tary Data  
      
Normal Symatlas Ge Total   
#Samples 158 36 194   
Source SymAtlas 
Supplemen
tary Data    
Table 4.2  Independent Data Sets Used for the External Validation 
The first row indicate the name of data set; the 2nd row is the number of samples 
in the data set; and the 3rd row is the source to access the data set. 
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We found that both the PGC genes were tightly regulated in all nine cancer 
sets (p-values: 0 ~ 0.002 hypergeometric distribution) (Table 4.2), confirming that 
the PGC is precisely controlled in a wide variety of solid tumors. We also 
performed the converse experiment and evaluated the regulation of the PGC in a 
series of independent non-malignant samples. Although such datasets are rarer in 
their availability than cancer datasets, we collected two distinct cohorts 
comprising 194 normal tissues from various organs (86, 87). These non-malignant 
samples were obtained from healthy donors and are thus free of malignancy and 
representative of true normal samples. The PGC genes were not tightly regulated 
in these normal data sets (p=0.07 and 0.01; Table 4.2).  Thus, these results 
indicate that that the precise regulation of the PGC genes is specific to cancer 
tissues, and suggests that diverse tumor types may harbor a general requirement 

























 13/348  3E-06 20/585    1E-17 27/1125    2E-8  




PGC 48 13/293   5E-07 9/410 0.002 




(79 Tissues)  
Ge (36) 
(36 Tissues)  
PGC 48 6/345 0.07 10/542 0.01 
 
Table 4.3  Validation of Precise Regulated Gene Expression Cassette in 
Independent Data Sets 
aNumber of genes in the original PGC signatures (eg, PGC = 48 genes) 
bNumber of PGC signature genes that are tightly regulated in the test sets (CV<0.28) 
cTotal number of tightly regulated genes in the test sets (CV <0.28) 
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dStatistical significance of PGC signature enrichment, calculated by the hypergeometric 
distribution test. P-values with significance (<0.01) are highlighted in bold 
eNumber of samples in the test data sets 
 
4.8 PGC Genes are Associated with Multiple Cancer 
Related Pathways 
Consistent with the PGC playing an important role in cancer, pathway analysis 
revealed multiple highly significant interactions between the PGC genes and 
prevalent tumorigenic pathways. We used Ingenuity Pathway Analysis (IPA, 
Ingenuity Systems) to identify molecular networks, cellular functions, and 
signaling pathways associated with the PGC. The various networks were 
displayed as nodes (genes) and edges (biological relationships between genes). 
We also used IPA to identify cellular functions and signaling pathways that were 
significantly enriched in the PGC. The significance of a pathway association is 
reflected by a Fisher’s exact test p-value, indicating the likelihood that the 
pathway would have been identified by random chance. 
The top-scoring molecular network for the PGC comprised 11 PGC focus 
genes interacting either directly or indirectly with the well-known cancer-related 
transcription factors Myc and TP53 (p=10-19) (Figure 4.6), and the most 
significantly enriched cellular functions for the top-scoring molecular network of 
PGC were cancer (p<0.0045), tumor morphology (p<0.0045) and cell cycle 
control (p<0.0045). The PGC was also significantly enriched in components 
related to integrin signaling (p=2.33E-04), a complex signaling pathway which 
can both positively and negatively regulate cell growth and cancer metastasis. 
Besides integrin components, other PGC genes, such as RPS2 and RPL7A, have 
also been implicated in the control of cellular transformation, tumor growth, 
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aggressiveness, and metastasis (88, 89); while the PGC gene MUS81 has recently 
been reported to interact with p53 to maintain genome stability in tumors (90). 
Thus, an array of biological and functional evidence suggests that the PGC genes 
are involved in the activity of multiple cancer-related pathways. The full list of 





Figure 4.6  Network analysis of PGC  
Top scoring PGC-associated network using Ingenuity. PGC were marked in bold 
with gray color. The networks are displayed graphically as nodes (genes/gene 
products) and edges (the biological relationships between the nodes).  As 
described in the Legend (top left panel), Nodes are displayed using various shapes 
that represent the functional class of the gene product.  Edges are displayed with 
various labels that describe the nature of the relationship between the nodes (e.g., 
E for expression, PP for protein-protein binding). The length of an edge reflects 
the evidence supporting that node-to-node relationship, in that edges supported by 
more articles from the literature are shorter. 
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4.9 Subtle Alterations in PGC Expression Are Associated 
with Metastatic Capacity of Cancer Cells 
PGC genes are robustly tight-regulated in cancer cells and involved in biological 
functions critical for cancer. These results suggested PGC might be the 
components of cancer-specific precise regulation system. To further test this 
hypothesis, we then explored if significant phenotypic differences might be 
associated with subtle alterations in PGC expression.  
First, we analyzed a set of colon cancer cell lines derived from either 
primary tumors or distant metastases from the same patient (SW480 and SW620), 
which have been shown to exhibit several phenotypic differences including 
metastatic potential (91, 92). Gene Set Enrichment Analysis (GSEA), a 
modification of the weighted Kolmogorov-Smirnov (KS) statistic provides a 
general statistical framework to test for the enrichment of a gene set in the gene 
expression profiles (54). GSEA considers a priori defined gene set, such as PGC 
in our case, and determines whether these members are enriched at the top (or 
bottom) of a list of markers ranked by the degree of correlation with a specific 
phenotype (eg, SW480 vs. SW620). The details of GSEA are provided in (54). 
Using Gene Set Enrichment Analysis, we found that PGC expression was subtly 
yet significantly decreased in highly metastatic SW620 cells compared to poorly 
metastatic SW480 cells (p<0.001).  
The PGC genes exhibited minimal expression variation across the lines 
when assessed using a standard range of expression variation, consistent with their 
being tightly regulated in cancers (Figure 4.7A, left heat-map). However, when 
the scale of variation was amplified, we identified by hierarchical clustering two 
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groups of cell lines showing either subtly higher or lower levels of PGC 
expression (Figure 4.7A, right heat-map). Importantly, we again found that the 
majority of cell lines with high to moderate invasive abilities exhibited subtle yet 
significant decreased expression of the PGC genes compared to poorly invasive 
lines (p=0.04, chi-square test, sample groups defined on the basis of the top-level 
branch point). To validate the robustness of this clustering by an alternative 
method, we then also performed independent k-means clustering (k=2). Using k-
means, 7 out of 8 highly invasive cell lines were clustered into one group together 
with 4 marginally or non-invasive cell lines (p = 0.01, chi-square test for high vs. 
marginal/non-invasive), consistent with the groupings observed by hierarchical 
clustering.  
Third, we generated our own murine xenograft model of metastasis, where 
poorly metastatic HCT116 colon cancer cells were injected into the spleens of 
nude mice, and metastatic liver tumor nodules were harvested 6 to 8 weeks later. 
The liver nodules were expanded in culture and re-passaged in mice to generate a 
panel of lines (M1, M2, and M3) with increasing levels of metastatic capacity 
(Figure 4.7B). Again we found that highly metastatic cells exhibited subtly 
decreased PGC expression compared to poorly metastatic HCT116 cells (Figure 
4.7B). In order to determine whether the expression of condition-dependent stable 
gene signature is correlated with the metastatic ability of cancer cells, we firstly 
quantify the metastatic ability of HCT116 and its derivations. We assigned [1 3 7 
10] to [HCT116 M1 M2 M3] based on the in vivo data (Figure 4.7B). We then 
calculated the correlation between the metastasis vector and expression values of 
TSS/NSS/PSS. GSEA was used to assess the significance of the correlation. 
GSEA showed the correlation was statistically significant (p=0.03).  To avoid the 
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arbitrary of assignment, we modified the metastasis vector to generate a number 
vectors with different scales: [1 2-4 7-9 10].  The correlation analysis was 
performed on each vector. The significance remain valid upon different 
quantification of metastasis vector (p<0.05, see Appendix Table 4.8).  
These results, based on three different experimental models of metastasis, 
collectively suggest that small alterations in PGC expression in tumors may be 







Figure 4.7  Subtle Alteration of PGC Expression is associated with invasion 
and metastasis in vitro  
A) Variation in PGC expression in breast cancer cell lines with differing invasive 
capacities. (Left) Expression heat-map depicting the range of PGC expression 
under a normal scale of variation, based on the top 900 varying genes in the data 
set (-6 to 6.6 fold, top scale bar). Under this normal scale, the PGC genes (blue 
column) are near black and show minimal expression variation across the cell 
lines. (Right) Expression heat-map depicting the range of PGC expression under a 
magnified scale of variation (-1.7 to 0.78 fold, compare purple bars between the 
left and right heat-maps). This heat-map represents the predominant pattern of 
Figure 4.7 
 77 
gene expression, and does not contain 13 outlier PGC genes (see Appendix Fig. 
4.10). It worth noting that unsupervised hierarchical clustering based on the entire 
48 PGC gene set was used to segregate the cell lines. Chi-square tests comparing 
the numbers of lines with none metastatic capacities in the two groups were 
assessed using the top level branch in the clustering tree (red arrows). Invasive 
capacities of the cell lines (none, high, marginal) were derived from Neve et al., 
2006 (85).  
B) Xenograft model of metastasis. Bar chart depicting the increasing metastatic 
potential of M1 to M3 cell lines compared to parental HCT116 cells. The x-axis 
depicts the number of metastatic modules observed per mouse, while the y-axis 
depicts the number of mice used in each experiment (n=5 to 7 mice per cell line).   
C) Expression heat map showing expression of the PGC signature in HCT116, 
M1, M2, and M3 cell lines, aligned from top to bottom. Three independent 
biological replicates were profiled for each cell line. Red, black and green squares 
indicate high, moderate, and low expression respectively. Individual PGC gene 
names are listed below the heat-map. Note that the range of expression variation 
across the lines is very small, as shown by the scale-bar (-0.8 to 0.8 fold). This 
heat-map represents the predominant pattern of gene expression, and does not 
contain 8 outlier PGC genes (see Appendix Fig 4.10). Once again, the 
unsupervised hierarchical clustering based on the entire 48 PGC gene set was used 




4.10 siRNA-mediated Knockdown of Multiple PGC Genes 
Enhance Cellular Invasion 
To directly demonstrate the functional role of PGC genes in cellular 
invasion, we performed siRNA experiments where five PGC genes (p53CSV, 
MAP3K11, MTCH2, CPSF6, SKIP) were silenced in poorly-metastatic AGS 
gastric cancer cells. While p53CSV is a gene required for p53-mediated cell 
survival (93), its role in cancer is otherwise poorly understood. Furthermore, 
associations between MAP3K11, MTCH2 and CPSF6 to cancer have also not been 
previously reported. The siRNA treatments reduced the expression levels of these 
five PGC genes from 45%-80%, as assessed by quantitative real-time PCR (Figure 
4.8A), and reductions in p53CSV, MAP3K11, MTCH2 and CPSF6 resulted in a 
significant enhancement of in vitro invasive activity as measured in a matrigel 
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assay (p<0.01, one-tailed t-test, Figures 4.8B and 4.8C). Furthermore, SKIP 
siRNA treatment resulted in a significant inhibition of cellular proliferation in 
AGS cells (p<0.01, Figure 4.8D). It is worth noting that for at least two genes 
(p53CSV and CPSF6), a partial reduction of gene expression of 45-60% was able 
to trigger a significant change in invasive phenotype.  To further demonstrate the 
generality of this phenomenon, we then knocked down p53CSV in another poorly-
metastatic colon cancer cell line, HCT116 which we previously utilized in the 
xenograft assay. Again, the partial silencing of p53CSV expression significantly 
increased the invasion activity of HCT116 cells (Appendix Fig. 4.11). These 




Figure 4.8 Reducing PGC gene expression by siRNA enhances the invasive 
behavior of AGS gastric cancer cells 
Figure 4.8 
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A) Real-time PCR quantification of siRNA mediated knockdown efficiency of 
five PGC genes (p53CSV, MAP3K11, MTCH2, CPSF6 and SKIP).  The y-axis 
represents the percentage of relative silencing achieved by the different siRNA 
treatments. Relative silencing was calculated by comparing PGC gene expression 
levels between cells treated with either control or PGC target siRNAs. For each 
siRNA treatment, the expression levels of the PGC genes were normalized against 
the GADPH expression level.  
B) Representative photographs of AGS cells in the matrigel invasion assay. The 
left panel depicts control siRNA treated cells, while the right panel indicates 
p53CSV siRNA treated cells. Note the increased number of invading cells in the 
right panel.  
C) Summary graph of invasion effects caused by PGC gene silencing. Significant 
enhancements in cellular invasion were observed for p53CSV, MAP3K11, MTCH2, 
CPSF6 (* symbols, P<0.01). P-values were calculated using a one-tailed t-test.    
D) Summary graph of cell proliferation effects caused by PGC gene silencing. 
Significant reductions in cell proliferation were only observed for the SKIP 




4.11 Subtle Alterations in PGC Expression are associated 
with Survival Outcome of Cancer Patients 
To extend the potential role of precise PGC regulation to the clinical 
context, we asked if similar small changes in PGC expression might be associated 
with significant differences in patient survival and clinical outcome. We employed 
hierarchical clustering to group the tumors in each of the six data sets with 
survival data available by their overall level of PGC expression. A representative 
example is shown in Figure 4.9A. Once again, the PGC genes exhibited minimal 
expression variation across the tumors when assessed on a standard scale of 
expression variation, consistent with their being tightly regulated in tumors 
(Figure 4.9A, left heat-map). However, when the variation scale was amplified, 
we identified two groups of tumors showing either subtly higher or lower levels of 
PGC expression (Figure 4.9A, right heat-map).  Remarkably, a Kaplan-Meier 
survival analysis revealed that in all six data sets, patients with tumors expressing 
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PGC levels below the population average experienced significantly worse survival 
outcomes compared to patients with high-PGC expressing tumors (Figure 4.9B; 
all cases p<0.05 except in ovarian cancer set where p=0.057, see Appendix Fig 
4.12 for clustering groupings). We only observed comparable survival 
stratifications across the six data sets in 46 out of 10,000 randomly selected 48-
member gene sets, arguing that the prognostic ability of the PGC is statistically 
unique. In a multivariate analysis, PGC expression behaved as an independent 
prognostic factor compared to other clinical variables in the breast and colon 
cancer cohorts, and was associated with tumor stage in ovarian, lung and glioma 
cancer patients (Table 4.4).  
 
Figure 4.9  PGC Expression in Primary Tumors Predicts Clinical Outcome 
A) Variation in PGC expression in primary breast tumors. (Left) Expression heat-
map depicting the range of PGC expression under a normal scale of variation, as 
assessed by the top 900 varying genes in the Wang_Breast data set (-11 to 7 fold, 
top scale bar). Under this normal scale, the PGC genes (blue row) are near black 
and show minimal expression variation across the tumors. (Right) Expression 
heat-map depicting the range of PGC expression under a magnified scale of 
variation (-0.39 to 0.35 fold, compare orange bars between the left and right heat-
maps). Unsupervised hierarchical clustering was used to segregate the tumors. All 
subsequent Kaplan-Meier analyses were performed between groups defined by the 
top level tree branch (purple and green samples).  
B) – E) Kaplan-Meier survival analysis of patient groups stratified by the PGC 
expression in primary tumors. Significantly distinct survival outcomes were 
Figure 4.9 
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observed in patients whose tumors express increased PGC levels compared to 
low-PGC expression patients, in the B) Wang_Breast set (p=0.015), C) 
Sotiriou_Breast (p=0.003), D) Bild_Lung (p=0.014), and E) Bild_Ovarian cancer 
cohorts (p=0.057), F) Phillips_Glioma cancer (p<0.001), and G) Aronow_Colon 
cancer cohorts (p=0.005). The outcome metric was relapse-free survival for B), 
C), and G) and overall survival for D), E) and F). 
 
 
Data Set p-value Hazard ratio  (95% CI) 
Sotiriou_Breast 
  Lower Upper 
PGC 0.02 0.15 0.03 0.74 
grade 0.15 1.68 0.83 3.39 
node 0.31 0.48 0.11 2.01 
size 0.13 1.47 0.89 2.44 
age 0.85 1.01 0.93 1.09 
     
Wang_Breast 
    
PGC 0.01 0.47 0.27 0.80 
ER 0.18 0.70 0.41 1.18 
     
Bild_Lung 
    
PGC 0.66 0.92 0.62 1.35 
Stage 0.03    
1 0.84 1.16 0.27 5.01 
2 0.93 1.07 0.21 5.40 
3 0.09 3.69 0.82 16.58 
     
Bild_Ovarian 
    
PGC 0.07 0.65 0.41 1.04 
Stage (III vs. IV) 0.04 0.52 0.27 0.97 
 
 
   
Phillips_Glioma     
PGC 0.09 0.52 0.24 1.11 
age 0.52 1.01 0.98 1.04 
Stage 0.09 0.50 0.22 1.13 
Gender 0.92 0.97 0.55 1.71 
     
Aronow_Colon 
    
PGC 0.007 0.20 0.06 0.65 
M 0.13 9.02 0.54 151.66 
N 0.34 1.89 0.51 7.07 
T 0.11 2.84 0.78 10.36 
DUKESTAGEa 0.92 0.00 0.00 2.15E+52 
size 0.73 0.95 0.73 1.25 
age 0.27 0.97 0.92 1.02 
AJCCSTAGE 0.93 279.96 0.00 3.80E+57 
Gender 0.74 0.81 0.24 2.78 
Table 4.4  Multivariate analysis for PGC in primary tumors 
Note: We performed multivariate analysis using Cox regression (SPSS) to 
determine if the prognostic ability of the PGC was independent or associated with 
other known clinical variables. PGC expression behaved as an independent 
prognostic factor for survival in the two breast cancer data sets (Wang and 
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Sotiriou) and colon data set when compared to other important determinants of 
patient survival such as estrogen receptor (ER) status. PGC expression was not an 
independent prognostic factor in the lung, ovarian and glioma cancer, and was 




4.12 PGC is Independent From Previous Published Gene 
Signatures 
We also asked if there was any substantial overlap between the PGC and other 
expression signatures derived from multiple tumor types, particularly those 
reported to predict clinical behavior. We compared the PGC against a 128-gene 
metastasis signature (MS) (11), a 70-gene chromosomal instability signature 
(CIN70) (94), a cell cycle module (95), a wound response healing signature (58, 
96),  and multiple cell proliferation-related signatures (57-59) including a 874-
gene cell cycle gene signature (CPS) (97). There was no direct overlap in gene 
content between the PGC and these other “multi-tumor” gene signatures, except 
for a one-gene overlap with the CIN70, and a four-gene overlap with the CPS, 
which was not statistically significant. This finding indicates that the specific gene 
content of the PGC is distinct from other previously described signatures. 
To ask if the PGC might target the same “poor prognosis” tumors as other 
published signatures capable of predicting clinical outcome in multiple tumor 
types, we investigated the ability of the MS, CIN70, and CPS to stratify patient 
survival in the six data sets - none of these signatures exhibited comparable 
prognostic significance to the PGC across the six patient cohorts (data not shown). 
This result suggests that the PGC is likely to target different molecular features 




4.13 PGC is Possibly Transcriptional Regulated by Myc 
Given the reality of a dynamic extracellular and intracellular microenvironment, it 
is reasonable to assume that many of these key genes are likely to possess 
complex regulatory systems for tightly regulating expression levels, and for 
rapidly sensing and adapting to perturbations in both the internal and external 
environment (98). Such mechanisms could involve the use of both positive and 
negative feedback loops, analogous to the circuitry utilized by the LacI/O bacterial 
system to ensure precise expression, but in cancers could also involve eukaryote-
specific mechanisms like epigenetic modifications (DNA methylation or 
chromatin modifications), microRNA regulation, or transcription factor binding.  
Interestingly, in a preliminary analysis, we attempted to extend our 
observations from the pathway analysis showing an association of several PGC 
genes with both Myc and TP53.  Specifically, we investigated whole-genome 
transcription factor binding data for Myc and TP53 as measured by chromatin 
immunoprecipitation coupled with pair-end-ditagging (ChIP-PET) technology 
(99). Myc genomic binding sites were identified by ChIP-PET in p493 human 
Burkitt's lymphoma cells expressing high levels (Myc-induced) or low levels 
(Control) of exogenous c-Myc under the control of tetracycline (99). P53 genomic 
binding sites were identified in HCT116 after 5-fluorouracil stimulation (100). We 
found that the PGC genes were weakly but significantly associated with Myc 
binding sites under Myc-overexpressed (tumorigenic) conditions (p=0.04) but not 
under physiological conditions (p=0.3) (Table 4.4). These preliminary results raise 
the possibility that transcription factor binding, specifically Myc binding, may 
constitute one possible mechanism for PGC regulation in cancer cells. However, 
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 Myc-Induced Control 
P53b 
TF-binding genes 
in 5729-gene set 390c 227 144 
 
PGC 0.042 7d 0.296 3 1 0 
Table 4.5  Association between PGC Genes and Myc/p53 Genome Binding 
loci  
a c-myc genomic binding sites identified by ChIP-PET in a human B cell line p493 
expressing either high (turomrigenic) or low levels (physiological) of c-Myc under 
the control of a tetracycline-repressible promoter (99).  
b P53 genomic binding loci in HCT116 after 5-fluorouracil stimulation (100).  
PET clusters of size >=3 were used for analysis. P-values were calculated by 
hypergeometric distribution test and the significant values (p<0.05) are marked in 
bold.   
c Number of genes with Myc or P53 binding loci in the 5,729-gene set 





In this study, we identified a novel cassette of genes exhibiting tumor-specific 
precise regulation in multiple cancer tissues. Our ability to discern the PGC was 
facilitated by the use of an analysis method focused on expression variance rather 
than expression levels. The reduced variance of the PGC in tumors is unlikely to 
be a technical artifact of the Affymetrix platform, as it was not related to probe 
selection, data normalization, absolute high or low expression levels in either 
tumors or non-malignant tissues, or sample set. Using both rigorous cross-
validation (RSS) and multiple independent validations, we found the PGC to be 
robust to alterations in training set composition and repeatedly observed in diverse 
malignant tumor types, including several tissue types not present in the original 
training data. Importantly, the PGC failed to demonstrate tight regulation in 
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several non-malignant tissue data sets, arguing that its control is cancer-specific. 
Interestingly, even though it was not a specific requirement in our initial analysis, 
the majority of PGC genes exhibited similar mean expression levels in both 
tumors and non-malignant tissues. This absence of a distinct difference in mean 
expression values resulted in the failure of standard microarray analysis methods 
(eg, SAM) to detect the majority of PGC genes when applied to the same training 
data set. Furthermore, a standard practice in microarray data processing is to filter 
out genes exhibiting low variation prior to clustering or statistical analysis - such 
filtering would inevitably lead to a bias towards differentially expressed genes and 
prevent the discovery of the PGC. Thus, the PGC genes are likely to be distinct 
from the conventional differentially expressed gene signatures described in most 
microarray studies. 
Besides cancer, this approach is conceptually applicable and easily 
transportable to other disease conditions where gene expression data is available. 
It will be interesting to explore if the approach will also prove informative in 
identifying genes and pathways with important roles in other human 
pathophysiologies.  
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Chapter 5. Conclusion and Discussion 
 
5.1 Conclusion 
The conventional analytic methods used in microarray studies have certain 
limitations that prevent the comprehensive data mining of the richness of gene 
expression data. These classical methods fail to take into consideration important 
biological aspects and may provide incomplete results in certain situations. We 
provided two novel approaches to analyze the gene expression data of human 
cancer disease. Both approaches overcome the limitation of conventional methods 
by taking into account the biological characters of microarray data. The results in 
Chapter 3 and Chapter 4 demonstrated our approaches can lead to the discovering 
of novel biological knowledge with a strong clinical implication. Moreover, both 
strategies are generally applicable to gene expression data of other diseases 
besides cancer.   
 
5.2 Biological Function of Genes Found in TuM1 
Tumor module 1 (TuM1) is a pro-apoptosis module and is associated with low 
tumor grade and tamoxifen response. Many of the genes in TuM1 have intriguing 
functions relevant to tumor biology, cell death, and treatment response. A few 
such examples are discussed here. For example, programmed cell death 4 
(PDCD4) has been shown to inhibit the growth of tumor cells (101); gap junction 
protein, alpha 1, 43kDa (connexin 43) (GJA1) has been reported to suppress cell 
proliferation and tumorigenicity of human glioblastoma cell (102) and to enhance 
apoptosis in response to chemotherapeutic agents (103). In addition, 
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mitochondrial ribosomal protein S30 (MRPS30) has been reported as a pro-
apoptotic gene that encodes protein programmed cell death 9 (104), while leucine-
rich repeats and immunoglobulin-like domains 1 (LRIG1) is a negative regulator 
of the ErbB family of receptor tyrosine kinases and has been suggested to 
suppress ErbB receptor –induced cell cycle progression (105). Besides apoptosis-
related genes, TuM1 also contains beta-TrCP1 (also known as Fbwla or FWD1), a 
component of the SKP1-cullin-F-box ubiquitin protein ligase complex, which can 
activate the NF-kappaB (NFκB) pathway and repress cell proliferation (106). 
Intriguingly, some genes in TuM1 have also been linked to clinical treatment 
response as well : inactivation of PDCD4 in human cancers has also been reported 
to cause decreased sensitivity to both geldanamycin and tamoxifen in breast 
cancer in vitro (107), while NAT1, another TuM1 gene, has been reported as an 
independent prognostic factor of breast cancer relapse and potential predictor of 
tamoxifen response (108). 
Clinically, a major feature of the TuM1 module is its association with low 
histological grade in an ER-independent manner. It is well known that histological 
grade strongly correlates with ER status in breast cancer, with ER negative tumors 
being predominantly high grade (grade 3). Because of the strong association 
between ER status and grade, previous reports attempting to identify ‘grade 
signatures’ using supervised learning methods, in which genes exhibiting the 
strongest expression differences between high grade and low grade breast tumors 
are selected, have tended to define ‘low-grade’ signatures containing multiple ER-
related genes such as GATA3 (24), which could represent possible confounders. In 
contrast, the TuM1/‘low grade’ association is independent of ER status, as 
confirmed by multivariate analysis. As for genes up-regulated in high grade breast 
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tumors (“high grade signatures’), the majority appear to be related to cellular 
proliferation (24). Of interest, we have previously identified a gene signature for 
the Nottingham Prognostic Index (NPI) in ER+ tumors, where tumor grade is a 
major component of the NPI. This previous result also suggests that cell 
proliferation gene signatures are correlated with grade in an ER-independent 
manner as well (56).     
5.3 TuM1 Predicts Tamoxifen Response of ER+ patients 
Functionally, we have also shown in this report that the TuM1 module is 
expressed in the ER+ MCF7 cell line and is the only breast cancer TuM that is 
significantly responsive to tamoxifen treatment. Futhermore, siRNA experiment 
showed at least one of the TuM1 genes RLN2 mediate the tamoxifen response in 
the ER+ breast cancer cells. NAT1, another TuM1 gene, has been reported as an 
independent prognostic factor of breast cancer relapse and potential predictor of 
tamoxifen response (108). These results suggest that expression of the TuM1 
module might represent a potential ‘molecular signature’ of tamoxifen response. 
The utility of TuM1 as an in vivo biomarker of tamoxifen response is further 
supported by our observation that TuM1 is associated with clinical outcome in 
multiple independent ER+ patient cohorts receiving tamoxifen treatment. This 
intriguing but preliminary finding definitely deserves further study and validation 
on a larger cohort of patients, supported by careful experiment design and data 
analysis. A prospective validation further supported the association between 
TuM1 and tamoxifen response. Interestingly, in the two independent ER+ patient 
cohorts where patients did not receive adjuvant treatment, patients with TuM1-
expressing tumors also exhibited a trend towards improved clinical outcome, 
however these differences were not statistically significant (p=0.48 for Rosetta 
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(12) and p=0.07 for Veridex data set (44). This is consistent with the hypothesis 
that the TuM1 module may have a better ability to predict a patient’s response to 
treatment than the intrinsic aggressive of the disease, ie the TuM1 signature is a 
predictive, rather than prognostic, signature.  
 
5.4 Methodology discussion – Biclustering  
The microarray compendia consist of measurements in multiple biological 
conditions and not all the conditions are truly most relevant to the biological 
question at hand. Therefore, simultaneous identification of the appropriate subset 
of experimental conditions and gene sets, often referred to as biclustering, has 
become a profitable extension to classical cluster analysis. Biculstering takes into 
account the fact that some genes are only tightly coexpressed in a subset of 
experimental conditions. In contrast, classical clustering (eg, hierarchical 
clustering) cannot always recover such sets of genes if the coexpressed patterns 
are obscured by a large set of irrelevant conditions (109). Furthermore, the 
discovery of relationships between genes and experimental conditions may be 
useful to reveal genetic pathway. 
(Iterative) Signature Algorithm is one of the few existing algorithms allow 
the discovery of a set of genes and its conditions, with the terms ‘module’ or 
‘bicluster’. Gene Expression Mining (110) and Gene Recommender (111) provide 
the similar functions. Recently, a Bayesian query-driven biclustering method has 
also been reported (112). This method is in principle similar to the Iterative 
Signature Algorithm, with a sounder mathematical framework. It worth noting 
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that it has been reported the performance of ISA is competitive with other 
biclustering methods (112).  
 
5.5 Integrative Systems Biology – Go beyond Gene 
Expression 
The coexpressed ‘module’, which is derived solely from gene expression data, can 
be incorporated with other data sources such as genomics alteration, transcription 
factor binding, protein-protein interaction, and miRNA targets. This ‘integrative 
system biology’ approach, though still in an early development, has been 
demonstrated its power in cancer research (95). This strategy can be naturally 
extended to our results. For instance, TuM1 may share the ERE (estrogen 
response element) binding sites since TuM1 genes are upregulated only in ER+ 
tumor. It will be interesting to see whether there are other co-transcription factors 
regulating TuM1 genes, in the combination with estrogen receptor. This may not 
only answer the question why TuM1 genes are overexpressed in only a subset of 
ER+ tumor, but also reveal the mechanism of regulating the tamoxifen response in 
ER+ cancer cells.  
 
5.6 PGC Genes are Involved in Carcinogenesis 
In Chapter 4 we reported a group of genes that are tightly regulated in cancer cells. 
One possible explanation for why certain genes may require precise control is if 
they regulate or are involved in balancing disparate downstream pathways 
possessing mutually opposing activities. In cancers, the successful establishment 
of a malignant tumor involves multiple pro- and anti-oncogenic forces involved in 
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cell proliferation, apoptosis, cell death, senescence, cell adhesion, and motility, all 
of which require delicate balance by different genetic components. For example, 
while loss of Ras signaling is lethal, aberrant signaling through this pathway is 
important for cancer development but can also drive cells into either senescence or 
cell proliferation, depending on cellular context (113, 114). Another good 
example is the anti-apoptotic gene Akt/PKB (protein kinase B), which when 
constitutively activated reduced metastases in mice and inhibited the invasion of 
breast cancer cells (115, 116), indicating its involvement in multiple cancer 
pathways. Reassuringly, similar examples of balanced coordinator genes are also 
seen in the cohort of PGC genes. The PGC gene FUS1 (also known as FUS) has 
been reported as a tumor suppressor gene in lung and breast cancer (117) and a 
pro-oncogene in leukemia (118). Oxidative stress, which may play an important 
role in cancer progression and the regulation of cancer metastasis (23), is 
dependent upon the critical balance between intracellular hydrogen peroxide H2O2 
and superoxide O2-. Two PGC genes - p53CSV and KIAA0247 have been reported 
to be induced in response to oxidative stress (119), and may influence this balance 
and the response of tumor cells to apoptotic stimuli (120). It is also worth noting 
that the PGC was significantly overrepresented in components of the integrin 
signaling pathway - a highly complex process involving multiple related family 
members with roles in many cellular functions, including ERK/MAPK and 
JNK/SAPK regulated gene expression, cell motility, cytoskeletal interactions, and 
PI3K and Wnt pathway signaling (121). In metastasis, integrins are crucial for cell 
invasion and migration, not only for physically tethering cells to the matrix, but 
also for sending and receiving molecular signals regulating these processes (121). 
Moreover, while some groups have proposed that increased integrin expression 
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could promote malignant behavior by enhancing tissue stiffness (122), other 
groups have suggested that loss of integrins may promote tumor invasion and 
metastasis (123). The complexity of integrin family members and their pathway 
components also provides a plausible explanation for why even subtle alterations 
in PGC expression are associated with distinct and measurable changes in 
metastatic behaviour in both experimental models of metastasis and clinical 
outcome. 
One potential concern might be that the PGC genes simply reflect the 
activity of tissue-specific gene expresison. However, we believe at least four 
findings argue against this possibility. First, while dedifferentiated cancer cells 
frequently exhibit a loss of tissue-specific gene expression (76), such a loss would 
typically result in tissue-specific genes being down-regulated in their absolute 
expression levels compared to normal tissues. In contrast, the PGC genes do not 
exhibit significant differences in their absolute expression levels between cancers 
and normal tissues (Figure 4.2B). Second, the reduced variation of the PGC genes 
was consistently observed in multiple independent sets from diverse tissues (eg 
gliomas, lung, breast), including a data set (NCC) that combined tissues from two 
different sources (gastric and NPC tumors). Third, the PGC genes also showed 
reduced expression variation in the NCI60 test set - a mixture of cancer cell lines 
from 9 different tissue types. Fourth, the PGC genes consistently exhibited 
reduced expression variation in the repeated random sampling (RSS) cross-
validation assay, where we tested 1000 distinct training set and independent test 
sets composed of mixed tissue types (Figure 4.4D). Fifth, even within each of the 
six tissue types in the training set (liver, colon, esophagus, thyroid, lung, and 
breast), the majority of the PGC genes (70%) are not differentially expressed 
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within tumors and normals (p>0.01, t-test) (YK, data not shown). Taken 
collectively, it is unlikely that the consistency of the PGC would have been 
observed if its reduced expression variation was solely due to tissue-specific 
expression, supporting the notion that the PGC genes are likely to be distinct from 
the conventional differentially expressed gene signatures described in most 
microarray studies. 
 
5.7 The Cancer Robustness  
Cancers have been proposed to possess robustness mechanisms for protection 
against various therapeutic perturbations and naturally occurring 
microenviromental (eg, hypoxia) and immune responses. However, many 
complex systems have evolved to exhibit a ‘robust yet fragile’ structure (124, 
125), and it has been proposed that studying mechanisms of cancer-specific 
robustness and accompanying fragilities might prove useful for the development 
of novel targeted therapies (126-128). The PGC gene cassette reported here may 
indicate such fragilities in the network of tumor cells, as subtle alterations on these 
components significantly affected the cellular behavior of cancer cells.   
 
5.8 The Normal-Specific PGC 
In chapter 4 we identified cancer-specific ultrasensitive components – PGC. It is 
not surprised to ask the question whether there is any ultrasentive component that 
is normal-specific. Similar as the cancer-specific PGC, we identified a group of 
genes which have a restricted expression variation in normal samples, compared 
to tumors. We also performed the same FDR (false discovery rate) and cross-
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validation assay on the normal-specific PGC and confirmed its robustness (data 
not shown). 
Interestingly, in the external validation the normal-specific PGC did not 
show restricted expression variation in all nine caner data sets (p-values: 0.2 ~ 
0.99), while cancer-specific PGC does (Table 4.3). In contrast to the cancer 
cohorts, the normal-specific PGC exhibited a restricted expression variation 
(p=3.3x10-5 and 4.9x10-7). These results, together with the results reported in 
Chapter 4, thus validate the PGC as a tumor-specific or normal-specific signature. 
The pathway analysis revealed that the normal-specific PGC genes were 
significantly overrepresented in biological pathways including Nucleotide 
Excision Repair (p=0.0007) and NF-κB signaling (p=0.0056) (Ingenuity). Thus, 
the normal-specific PGC signatures appear to be associated with pathways 
regulating normal cellular maintenance, contrast to the observation that cancer-
specific PGC are functionally involved in neoplastic development. The normal-
specific PGC genes were not correlated with cancer metastasis or patient’s 
survival outcome.  The normal-specific PGC likely represent a ‘defensive’ 
molecular mechanism against carcinogenesis. It will be valuable to explore the 
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Table 3.7 Clinical information for Breast Tumors 
Sample ID Age Size (mm) Grade LN ER PR LVI 
980058 72 45 3 0 of 12 pos pos no 
980177 75 26 2 6 of 13 pos pos yes 
980178 69 32 3 2 of 15 pos neg no 
980193 49 25 3 3 of 23 neg neg no 
980194 58 50 3 25 of 32 neg neg yes 
980197 55 30 3 2 of 4 pos pos yes 
980203 44 15 1 0 of 11 pos pos no 
980208 42 25 3 5 of 20 pos pos no 
980214 49 60 2 5 of 13 pos neg no 
980215 50 30 2 8 of 23 pos neg no 
980216 65 45 2 5 of 20 neg neg no 
980217 50 30 2 7 of 12 pos neg yes 
980220 40 37 2 0 of 5 pos pos yes 
980221 33 65 3 1 of 13 pos pos no 
980238 62 20 3 7 of 21 neg neg no 
980247 35 45 3 1 of 19 neg neg yes 
980256 46 36 3 1 of 12 neg neg no 
980261 60 15 2 0 of 9 pos neg no 
980278 64 40 3 14 of 20 pos neg yes 
980285 49 40 3 1 of 7 neg neg yes 
980288 45 60 3 13 of 15 pos neg yes 
980315 59 45 3 0 of 19 neg neg yes 
980333 51 40 3 2 of 7 pos pos no 
980335 33 3 3 3 of 7 neg neg yes 
980338 55 30 3 0 of 7 neg neg no 
980346 52 20 3 0 of 4 pos pos possible 
980353 58 45 3 0 of 25 neg neg no 
980373 77 30 3 0 of 14 neg neg no 
980380 56   0 of 6 neg neg  
980383 64 30 2 0 of 16 pos pos no 
980391 56 20 2 0 of 7 pos pos no 
980395 68 30 3 1 of 10 neg neg yes 
980396 66 35 3 10 of 12 neg neg yes 
980403 73 30 3 0 of 9 pos pos possible 
980404 46 30 2 1 of 5 pos pos yes 
980409 48 15 2 0 of 19 pos neg no 
980411 69 30 2 0 of 9 neg neg no 
980434 73 30 3 0 of 16 pos pos no 
980441 66 30 3 4 of 14 neg neg yes 
990075 66 25 3 5 of 21 pos pos yes 
990082 49 34 2 3 of 16 pos pos no 
990107 50 40 1 1 of 18 pos neg yes 
990113 70 90 3 11 of 15 pos pos no 
990115 38 28 3 9 of 10 pos pos yes 
990123 54 55 3 7 of 11 pos pos no 
990134 43 40 3 0 of 19 neg neg no 
990148 60 40 2 6 of 19 pos neg yes 
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990174 55 45 2 3 of 24 neg neg yes 
990223 52 5 3 1 of 21 pos neg no 
990262 68 40 3 4 of 14 neg neg no 
990299 58 55 3 7 of 17 neg neg possible 
990375 38 15 1 0 of 10 pos neg no 
2000104 59    pos neg  
2000171 50 25 2 0 of 9 neg neg no 
2000209 58 50 3 0 of 7 pos neg no 
2000210 50 40 3 3 of 6 neg neg yes 
2000215 50 15 2 1 of 21 pos pos no 
2000220 52 60 3 30 of 34 pos neg yes 
2000237 43 47 3 23 of 40 pos pos yes 
2000272 49 30 3 1 of 16 pos neg yes 
2000274 40 35 3 10 of 23 pos pos yes 
2000287 53 40 3 0 of 8 neg neg possible 
2000320 67 20 3 20 of 21 neg neg yes 
2000376 65  3 8 of 23 neg neg yes 
2000399 44 40 2 0 of 8 neg neg no 
2000401 51 50 3 2 of 6 neg pos no 
2000422 51 63 3 3 of 7 pos pos no 
2000500 44 75 3 6 of 6 neg neg yes 
2000593 60 41 3 0 of 15 neg neg no 
2000597 57 40 2 0 of 12 pos neg possible 
2000609 62 70 2 17 of 17 pos pos yes 
2000638 60 40 1 0 of 15 pos neg no 
2000641 47 60 3 16 of 24 neg neg yes 
2000651 45 41 2 3 of 5 pos pos yes 
2000652 56 25 3 6 of 21 neg neg no 
2000675 78 55 3 16 of 16 neg neg yes 
2000683 72 35 2 0 of 17 pos pos no 
2000709 45 30 3 0 of 16 neg neg no 
2000731 68 51 3 1 of 29 pos neg no 
2000759 57 7 3 0 of 12 neg neg no 
2000768 39 40 3 0 of 17 pos pos no 
2000775 51 25 2 0 of 12 pos neg no 
2000779 48 55 3 0 of 14 pos neg no 
2000787 57 60 3 0 of 9 pos pos yes 
2000804 39 40 3 5 of 21 pos pos yes 
2000813 60 23 3 16 of 17 neg neg yes 
2000818 52 10 2 0 of 11 pos neg no 
2000829 51 45 2 10 of 10 neg neg yes 
2000880 55 15 2 0 of 26 neg neg no 
2000948 56 35 3 4 of 22 pos neg yes 
20020021 64 38 3 0 of 13 pos neg yes 
20020051 38 50 3 1 of 25 pos pos no 
20020056 71 20 1 2 of 17 pos neg no 
20020071 58 28 3 0 of 16 pos pos no 
20020090 60 45 3 19 of 27 neg neg yes 
20020160 86 120 3 0 of 10 pos pos no 
LN: lymph node; ER: estrogen receptor; PR: progesterone receptor; LVI: 
lymphovascular invasion 
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Table 3.8  The List of TuM1 genes  
 
Probe Gene Name Unigene 
218613_at hypothetical protein DKFZp761K1423 Hs.236438 
203355_s_at ADP-ribosylation factor guanine nucleotide factor 6 Hs.408177 
202731_at 
programmed cell death 4 (neoplastic 
transformation inhibitor) Hs.257697 
214440_at 
N-acetyltransferase 1 (arylamine N-
acetyltransferase) Hs.458430 
203404_at armadillo repeat protein ALEX2 Hs.48924 
202174_s_at pericentriolar material 1 Hs.348501 
217838_s_at Enah/Vasp-like Hs.241471 
219455_at hypothetical protein FLJ21062 Hs.276466 
221946_at hypothetical protein MGC29761 Hs.414028 
222314_x_at Homo sapiens, clone IMAGE:5759947, mRNA Hs.437867 
211596_s_at 
leucine-rich repeats and immunoglobulin-like 
domains 1 Hs.166697 
211538_s_at heat shock 70kDa protein 2 Hs.432648 
214705_at InaD-like protein Hs.436450 
218398_at mitochondrial ribosomal protein S30 Hs.124165 
201667_at 
gap junction protein, alpha 1, 43kDa (connexin 
43) Hs.74471 
215300_s_at flavin containing monooxygenase 5 Hs.396595 
209884_s_at 
solute carrier family 4, sodium bicarbonate 
cotransporter, member 7 Hs.250072 
212196_at 
interleukin 6 signal transducer (gp130, 
oncostatin M receptor) Hs.71968 
200648_s_at glutamate-ammonia ligase (glutamine synthase) Hs.442669 
214519_s_at relaxin 2 (H2) Hs.127032 
219114_at g20 protein Hs.21050 
206081_at 
solute carrier family 24 (sodium/potassium/calcium 
exchanger), member 1 Hs.173092 
214430_at galactosidase, alpha Hs.69089 
221562_s_at 
sirtuin (silent mating type information regulation 2 
homolog) 3 (S. cerevisiae) Hs.511950 
218149_s_at hypothetical protein DKFZp434K1210 Hs.32352 
214087_s_at myosin binding protein C, slow type Hs.169849 
213933_at prostaglandin E receptor 3 (subtype EP3) Hs.27860 
215014_at 
Homo sapiens mRNA; cDNA DKFZp547P042 (from 
clone DKFZp547P042) Hs.232127 
203143_s_at KIAA0040 gene product Hs.368916 
204901_at beta-transducin repeat containing Hs.226434 
209123_at quinoid dihydropteridine reductase Hs.75438 
213832_at Homo sapiens clone 24405 mRNA sequence Hs.23729 
207519_at 
solute carrier family 6 (neurotransmitter transporter, 







Table 3.9. Correlation between TuMs 1, 2, 3 and grade within ER positive tumors. In this 
analysis, only the ER positive tumors were used in the sample population. 1st column for 
each module indicated the number of TuM-overexpressed tumors. 
 
 
TuM1 TuM2 TuM3 
Grade P<0.001 P= 0.155 P= 0.341 
1 5 0 4 1 1 4 
2 7 12 8 11 7 12 
3 2 30 11 21 6 26 
 
Univariate association by using ER+ breast tumors only 
We also repeated the univariate association studies, this time using a sample set of 
only ER positive tumors (unlike the previous analysis where all tumors were 
used). In this “ER positive only” data set, we found that TuM1 still remained 
significantly correlated with lower tumor grade (p<0.001). In contrast, TuM2 and 
TuM3, which both contain several ER-related genes, failed to exhibit a significant 
correlation with tumor grade when the ER negative tumors were removed from 















0.24 10 25% 93% 
0.25 17 42% 98% 
0.26 16 60% 99% 
0.27 29 77% 100% 
0.28 48 80% 100% 
0.29 57 82% 100% 
0.3 64 88% 100% 
 
Note: The cross-validation procedures were the same as the repeated random sampling 
(RSS) test used in the Main text (see Methods). For each cut-off, the cross-validation was 
run 100 times.  
 
The percentages indicate: 1) true positive rate (1st column): how many times PGC is 
significantly enriched (p<0.01) in genes tightly regulated in the corresponding test set 
(PGC->Tumor); and 2) true negative rate (2nd column):  how many times PGC is NOT 
significantly enriched (p<0.01) in genes tightly regulated in the unmatched test set (PGC-
>Control). Within the CVT range (0.26~0.3), we obtained similar levels of sensitivity and 






Table 4.7  Gene List of PGC. The annotation was downloaded from 




Gene Title Gene 
Symbol 
go biological process term 
regulation of progression 
through cell cycle 
transcription 
regulation of transcription, 
DNA-dependent 
regulation of transcription, 
DNA-dependent 
immune response 
response to DNA damage 
stimulus 
ER overload response 
cell cycle 
cell cycle arrest 
regulation of cell redox 
homeostasis 
unfolded protein response 
mRNA transcription from RNA 
polymerase II promoter 
200959_at fusion (involved in t(12;16) 
in malignant liposarcoma) 
FUS 
regulation of apoptosis 
cell motility 
sensory perception of sound 
201550_x_at actin, gamma 1 ACTG1 
sarcomere organization 
208948_s_at staufen, RNA binding 






217740_x_at ribosomal protein L7a RPL7A 


















positive regulation of I-
kappaB kinase/NF-kappaB 
cascade 
negative regulation of 
progression through cell cycle 










long-term strengthening of 
neuromuscular junction 
proteasomal ubiquitin-
dependent protein catabolic 
process 
208980_s_at ubiquitin C UBC 
positive regulation of 
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transcription 
regulation of synaptic 
plasticity 
protein amino acid 
phosphorylation 
protein amino acid 
phosphorylation 







regulated kinase 1A 
DYRK1A 








214363_s_at matrin 3 MATR3 
  
myosin regulatory light 
chain MRCL3 
LOC645094 




  MRCL3 
regulation of smooth muscle 
contraction 
transcription from RNA 
polymerase II promoter 
206968_s_at nuclear factor related to 
kappaB binding protein 
NFRKB 
inflammatory response 
regulation of progression 
through cell cycle 




218004_at BSD domain containing 1 BSDC1 
  
endocytosis 
intracellular signaling cascade 
regulation of Rho protein 
signal transduction 
35776_at intersectin 1 (SH3 domain 
protein) 
ITSN1 
synaptic vesicle endocytosis 
transcription 212429_s_at general transcription factor 
IIIC, polypeptide 2, beta 
110kDa 
GTF3C2 
transcription from RNA 
polymerase III promoter 
transport 
intracellular protein transport 
ER to Golgi vesicle-mediated 
transport 
protein transport 
202798_at SEC24 related gene family, 







endosome to Golgi 
201807_at vacuolar protein sorting 26 
homolog A (S. pombe) 
VPS26A 
retrograde transport, 
endosome to Golgi 
mRNA processing 202469_s_at cleavage and 
polyadenylation specific 






211058_x_at tubulin, alpha 1b TUBA1B 
  
mRNA processing 212440_at putative nucleic acid 
binding protein RY-1 
RY1 
RNA splicing 




translation 201573_s_at eukaryotic translation 




regulation of translational 
termination 
DNA metabolic process 
DNA repair 
DNA recombination 
218463_s_at MUS81 endonuclease 
homolog (S. cerevisiae) 
MUS81 
response to DNA damage 
stimulus 
G1 phase of mitotic cell cycle 
activation of MAPK activity 
protein amino acid 
phosphorylation 




activation of JNK activity 
cell proliferation 
regulation of JNK cascade 
protein amino acid 
autophosphorylation 
203652_at mitogen-activated protein 








AASDHPPT macromolecule biosynthetic 
process 
217772_s_at mitochondrial carrier 
homolog 2 (C. elegans) 
MTCH2 transport 
rRNA modification 217106_x_at DIM1 dimethyladenosine 




transcription 220015_at castor zinc finger 1 CASZ1 
regulation of transcription, 
DNA-dependent 









209712_at solute carrier family 35 
(UDP-glucuronic acid/UDP-
N-acetylgalactosamine dual 
transporter), member D1 
SLC35D1 
  
protein amino acid 
phosphorylation 
signal transduction 
202544_at glia maturation factor, beta GMFB 
nervous system development 
transcription 
regulation of transcription, 
DNA-dependent 




222028_at zinc finger protein 45 ZNF45 
  
protein amino acid 
phosphorylation 
protein amino acid 
phosphorylation 
protein amino acid 
phosphorylation 
response to oxidative stress 
response to oxidative stress 
202696_at oxidative-stress responsive 
1 
OXSR1 
protein kinase cascade 
nuclear mRNA splicing, via 
spliceosome 
201575_at SNW domain containing 1 SNW1 
regulation of transcription 






targeting to membrane 
RNA splicing 
negative regulation of 
transcription 
regulation of progression 
through cell cycle 
cell cycle 
cell adhesion 
Rho protein signal 
transduction 
209390_at tuberous sclerosis 1 TSC1 
negative regulation of 
progression through cell cycle 
218582_at membrane-associated ring 
finger (C3HC4) 5 
MARCH5 ubiquitin cycle 
regulation of progression 
through cell cycle 
small GTPase mediated 
signal transduction 
Rho protein signal 
transduction 
203175_at ras homolog gene family, 
member G (rho G) 
RHOG 
positive regulation of cell 
proliferation 
fatty acid biosynthetic process 
acyl-CoA metabolic process 
lipid biosynthetic process 
short-chain fatty acid 
biosynthetic process 
219133_at 3-oxoacyl-ACP synthase, 
mitochondrial 
OXSM 




DNA damage response, 
signal transduction by p53 
class mediator resulting in cell 
cycle arrest 
218403_at TP53 regulated inhibitor of 
apoptosis 1 
TRIAP1 
DNA damage response, 
signal transduction by p53 
class mediator 








202181_at KIAA0247 KIAA0247 
  






induction of apoptosis 
RNA splicing 
200071_at survival motor neuron 
domain containing 1 
SMNDC1 
RNA splicing 






long-term strengthening of 
neuromuscular junction 
proteasomal ubiquitin-
dependent protein catabolic 
process 
positive regulation of 
transcription 
200633_at ubiquitin B UBB 
regulation of synaptic 
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plasticity 








Table 4.8  Association of the PGC expression with Metastatic Activity 
 
  Xenografta    
 
Humanb  
 p-value  p-value 
PGC 0.03  <0.001 
 
In both cases, PGC expression is inversely correlated with metastatic activity.  
 
a Associations between PGC expression and metastatic vector were calculated 
using Gene Set Enrichment Analysis (GSEA).  
b Comparison of PGC expression to cellular phenotype in isogenic colorectal 
cancer (CRC) cell lines from the same patient obtained from either primary or 
metastasis sites.  
 
P-values with significance (p<0.05) are highlighted in bold. 
 
 
b) Detailed results of GSEA on each of the nine metastasis vectors [1 2-4 7-9 
10]. 
 
  Summary of nine metastasis vectors   
 
 p-value (median) p-value  
(range) 
 
PGC 0.045 0.008 - 0.15  
 
Note:  The association between expression level of PGC and metastasis activity was 


























Figure 4.10  Clustering of Cell Lines Based on the 49 Gene Set 
Figure 4.11  Reducing p53CSV expression by siRNA enhances the invasive 
behavior of HCT116 colon cancer cells 
Figure 4.12  Heatmap of clustering of PGC in five tumor data sets 
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Figure 4.10 : Clustering of Cell Lines Based on the 48 Gene Set.  
While the clustering of the samples for Figures 3A and 3B was performed using 
the entire 48-member gene set, a few ‘outlier’ genes (13 genes for 3A and 8 genes 
for 3B) were removed from the figure since our attention was to focus on the 
dominant focused on the dominant PGC expression pattern. Here, we have now 
included the heatmaps with the complete set of 48 PGC genes. It is important to 
note that the clustering of cell lines is based on the expression pattern of the entire 
set of 48 PGC genes. 
 
            3A : Breast Cell Lines   3B : Mouse Xenograft 
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Figure 4.11 : Reducing p53CSV expression by siRNA enhances the invasive 
behavior of HCT116 colon cancer cells 
A) siRNA mediated knockdown of p53CSV in HCT116 cells. RT-PCR figure 
showing silencing of p53CSV gene in HCT116 cells. GAPDH was used as the 
internal control. 
B) Representative photographs of HCT116 cells in the matrigel invasion assay. 
The left panel depicts control siRNA treated cells, while the right panel indicates 
p53CSV siRNA treated cells. 
C) p53CSV silencing increases the invasive behavior of HCT116 cells in matrigel 
invasion assays. Relative invasion was scored with reference to control siRNA 
transfected cells. The average and range derived from three independent 










Figure 4.12 : Heatmaps of clustering of PGC in five tumor data sets 
Expression heatmaps of clustering of PGC on five tumor data sets. The survival 
analysis, which are shown in Figure 4.9 (main text), were performed based on the 
results of these clustering. The two groups of tumors were defined based on the 
top level node in the dendrogram. The clustering of Sotirioi_Breast data set was 
performed in four separate subsets (as described in the original paper ref. 83). The 
color bar (purple and gree line) is corresponding to the survival curves in Figure 
4.9. 
 
